Method for detecting contaminating carboxylesterase activity

By using a combination of hydrophilic and lipophilic substrates, along with buffer and non-denaturing detergent, the activity of carboxylesterase and lipase in contaminating host cell proteins in recombinant protein samples from eukaryotic cells can be rapidly detected. This solves the problem of detection difficulties in existing technologies and achieves efficient and sensitive detection results.

CN118901012APending Publication Date: 2024-11-05BOEHRINGER INGELHEIM INT GMBH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380024525.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-09
Filing Date
2023-03-08
Publication Date
2024-11-05

AI Technical Summary

Technical Problem

Existing technologies struggle to rapidly and sensitively detect the carboxylesterase and lipase activities of contaminating host cell proteins contained in recombinant protein samples produced in eukaryotic cells, particularly in the degradation of polysorbate during biopharmaceutical processes.

Method used

A combined approach using the hydrophilic substrate HPTS ester and the lipophilic substrate 4-MU ester was employed to rapidly detect carboxylesterase and lipase activities by measuring the fluorescence intensity of the chromophore. Samples were incubated in a pH range of 4 to 8 using buffered and unbuffered salts, and combined with a non-denaturing detergent to achieve high-throughput analysis.

Benefits of technology

It enables rapid and sensitive detection of carboxylesterase and lipase activities in contaminated host cell proteins, is suitable for small-volume samples, and is ideal for high-throughput analysis, reducing detection time and improving detection accuracy and sensitivity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005018883160000101
    Figure BDA0005018883160000101
  • Figure BDA0005018883160000221
    Figure BDA0005018883160000221
  • Figure BDA0005018883160000391
    Figure BDA0005018883160000391
Patent Text Reader

Abstract

The present invention relates to a method for detecting carboxylesterase activity of a contaminating host cell protein in a sample comprising a recombinant protein of interest produced in eukaryotic cells in cell culture, comprising contacting the sample with a hydrophilic substrate HPTS ester, and optionally additionally separately contacting the sample with a lipophilic substrate 4-MU ester, and detecting carboxylesterase activity and optionally lipase activity of the at least one contaminating host cell protein using a hydrophilic substrate and optionally a lipophilic substrate by detecting the fluorescence intensity of the released chromophore. Further provided are methods for making a recombinant protein of interest, comprising using a method for detecting carboxylase activity of a contaminating host cell protein in a sample comprising a recombinant protein of interest produced in eukaryotic cells in cell culture, hydrophilic substrates and optionally further lipophilic substrates are used for determining contaminating carboxylesterase activity and / or lipase activity in a sample comprising a recombinant protein of interest during manufacture.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a method for detecting the carboxylesterase activity of contaminating host cell proteins in a sample containing a recombinant protein of interest produced in eukaryotic cells in cell culture, which comprises contacting the sample with a hydrophilic substrate HPTS ester, and optionally separately contacting the sample with a lipophilic substrate 4-MU ester, and using the hydrophilic substrate and optionally the lipophilic substrate to detect the carboxylesterase activity and optionally the lipase activity of at least one contaminating host cell protein by detecting the fluorescence intensity of the released chromophore. A method for manufacturing a recombinant protein of interest is further provided, which comprises using the method for detecting the carboxylase activity of contaminating host cell proteins in a sample containing a recombinant protein of interest produced in eukaryotic cells in cell culture, using a hydrophilic substrate and optionally a further lipophilic substrate for determining the contaminating carboxylesterase activity and / or lipase activity in a sample containing the recombinant protein of interest during manufacturing. Background Art

[0002] Over the past few decades, proteins have become increasingly popular as therapeutic agents. Formulations containing therapeutic proteins such as monoclonal antibodies often contain high protein concentrations of 100 mg / ml or more and often require the presence of detergents. Due to their biocompatibility and low toxicity, the most widely used detergents in the biopharmaceutical industry are polysorbates (PS), such as polysorbate 20 (polyoxyethylene (20) sorbitan monolaurate, Tween ) or polysorbate 80 (polyoxyethylene (20) sorbitan monooleate, Tween ).

[0003] Polysorbate is a heterogeneous mixture of sorbitol and its anhydride together with about 20 polymerized ethylene oxide parts esterified by fatty acid moieties. However, polysorbate is easy to degrade, which can adversely affect the product quality. Degradation may affect product quality, not only due to the reduced polysorbate concentration in the resulting preparation, but also due to the formation of visible particles and invisible particles from the insoluble substances of polysorbate degradation products, such as fatty acids and polyoxyethylene side chains. Polysorbate can be chemically or enzymatically degraded. The chemical degradation of polysorbate is mainly caused by oxidation reactions, which especially lead to the formation of aldehydes, ketones and fatty acids. The enzymatic degradation of polysorbate is characterized by the hydrolysis of the ester bond connecting polyethoxylated dehydrated sorbitol to fatty acids (Dwivedi et al., 2018, International Journal of Pharmaceutics 552: 442-436). Although oxidative degradation of polysorbates has long been known, enzymatic hydrolysis of polysorbates in antibody formulations has only recently been recognized as one of the major degradation pathways. In recent years, polysorbate degradation has become a major challenge in the biopharmaceutical community.

[0004] It has been reported that residual host cell proteins (HCPs) with hydrolytic activity in the final drug product (DP), such as lipases and other esterases, including carboxylesterases, can lead to polysorbate degradation. The identified enzymes are mainly classified into the lipase class, a subclass of esterases that catalyzes lipid hydrolysis. The role of lipases in polysorbate degradation in antibody formulations has been further emphasized by Chiu et al., where harvested cell culture fluid (HCCF) from lipoprotein lipase (LPL) knockout CHO cells reduced PS20 and PS80 degradation compared to wild-type CHO cells (Chui et al., 2017, Biotechnol. Bioeng. 114, 1006-1015). In addition, group XV lysosomal phospholipase A2 isoform X1 (LPLA2), putative phospholipase B-like-2 (PLBL2), liver carboxylesterase, phospholipase A2 group VII (PLA2G7), lysophospholipase 2 (LYPLA2), lysosomal acid lipase (LIPA), sialyl acetylesterase (SIAE), palmitoyl protein thioesterase 1 (PPT1) and lipoprotein lipase (LPL) were also detected in activity-based protein profiling assays and the final drug product, indicating that these enzymes are potentially critical for PS degradation (Hall et al., 2016, Journal of Pharmaceutical Sciences, 105(5):1633-1642; Dixit et al., 2016, Journal of Pharmaceutical Sciences, 105(5):1657-1666; Zhang et al., 2020, Journal of Pharmaceutical Sciences, 105(5):1657-1666). Sciences, 109(11):3300-3307; Chiu et al., 2017, Biotechnology and bioengineering 114(5):1006-1015; Li et al., 2020, Anal. Chem., 93(23):8161-8169; Graf et al., 2021, Journal of Pharmaceutical Sciences, 110:3558-3567). However, some of these enzymes belong to the class of esterases that favor more hydrophilic substrates, such as carboxylesterases. The necessary changes and adjustments to upstream and especially downstream production processes in therapeutic protein production are difficult because it takes weeks to determine the effects of individual purification steps and conditions on polysorbate degradation.

[0005] Polysorbate content and degradation can be studied using different analytical techniques. The most commonly used method for quantitative polysorbate is reverse phase liquid chromatography (e.g. RP-HPLC), and this can be further coupled with evaporative light scattering detector (ELSD) and charged aerosol detector (CAD). Other techniques that can determine polysorbate content consist of fluorescent micelle determination (FMA) or chemical complexation of sorbitan ring with cobalt thiocyanate or ferric thiocyanate. However, in order to determine whether the changes in the purification process are successful in reducing the hydrolytic activity responsible for polysorbate degradation, the sample of interest needs to be spiked with polysorbate, and needs to analyze its degradation as described above. Therefore, polysorbate degradation is usually evaluated by monitoring the reduction of polysorbate content over a period of time. However, polysorbate degradation is a slow process that may take up to several weeks or months. Further, analysis is complicated and time-consuming.

[0006] In order to develop purification conditions that minimize enzymatic degradation of polysorbates in drug products, a rapid, reliable, automated, high-throughput assay with high sensitivity is needed that can be easily adapted to different samples and provides predictive information about the hydrolytic activity responsible for polysorbate degradation in drug substances of drug product samples. Such an assay can be used as a tool to guide process development for the production of drug substances with increased product quality due to minimization of polysorbate degradation activities co-purified with the target protein.

[0007] It is known in the art to use fluorescent substrates to detect the hydrolytic activity of lipases and carboxylesterases in vitro, but these prior art determinations are not sensitive enough to reliably detect the contaminating lipase activity in recombinant protein preparations in a short period of time, and the recombinant protein preparations are only co-purified from eukaryotic cells together with recombinant proteins (proteins of interest). For example, Tsuzuki et al., (Biosci.Biotechnol.Biochem, 2001, 65 (9): 2078-2082) analyzed the activity of several lipases from microorganisms at high concentrations using fluorescent substrates. Similarly, Yoo et al., (Cell Chemical Biology, 2020, 27: 143-157) discloses a fluorescent substrate assay for detecting lipase activity, and TritonX-100 is used to dissolve highly concentrated lipase rPfMAGLLP before analysis. WO 2010 / 024924 discloses the use of fluorescent substrates for screening the determination of lipases expressed in Escherichia coli (E.coli). Fluorometric assays for detecting the activity of hydrolases including carboxylesterases have been further reported by Wolfbeis and Koller (Analytical Biochemistry, 1983, 129: 365-370), but again only isolated and concentrated hydrolases have been tested. However, none of these assays describe the lipase activity of contaminating host cell proteins in samples containing recombinant proteins purified from eukaryotic cells.

[0008] Menden et al., 2019 (Journal of Enzyme Inhibition of Medicinal Chemistry, 34 (1): 1474-1480) reported a lipase activity assay in which the lipase activity of a limited enzyme extract of a Candida rugosa lipase (CRL) isoform was detected to verify the mode of action of the inhibitor tropolone using 4-methylumbelliferyl butyrate (4-MUB) and 4-methylumbelliferyl palmitate (4-MUP) as substrates. The limitations of the assay were reported, including the inherent decrease in solubility of the hydrophobic fatty acid tail with length and the autocatalysis of the substrate in the alkaline pH range. In addition, detergents were not used in the assay. Recently, Jahn et al., 2020 (Pharm. Res. 37 (118): 2-13) reported a chromophore-based lipase activity assay for determining polysorbate degradation in harvested cell culture fluid samples using 4-methylumbelliferyl oleate (4-MuO) as a substrate. However, moderate sensitivity still requires an incubation time of 24 hours or more. 4-methylumbelliferone-based substrates for detecting lipase activity have been further described by Bhargava et al., 2021 (Pharm Res. 38 (3): 397-413), WO 2022 / 047415 A1 and WO 2022 / 049294A1. These recent efforts illustrate the need for assays to detect polysorbate degradation activity during biopharmaceutical development. However, all of these assays focus on lipophilic substrates and lipase activity, using conditions that are conducive to certain polysorbate degradation enzyme activities, and therefore other polysorbate degradation activities may be ignored. Additionally, Bhargava et al., 2021 (PharmRes. 38(3):397-413) and WO 2022 / 047415 A1 note the following as limitations of the disclosed esterase activity assay: residual HCPs may differ in their hydrolysis activity against carboxylate ester bonds in MU-C8 versus PS20 or PS80, and the pH 8.0 used is not representative of the low pH used in parenteral drug products.

[0009] Accordingly, there is a need for a rapid and high-throughput method to broaden the scope of existing assays and to complement existing testing methods for detecting polysorbate-degrading enzymes such as carboxylesterases with high sensitivity. Summary of the invention

[0010] The present invention relates to a method for detecting carboxylesterase activity of a contaminating host cell protein in a sample comprising a recombinant protein of interest produced in a eukaryotic cell in cell culture, comprising (a) providing at least one sample comprising a recombinant protein of interest produced in a eukaryotic cell in cell culture and at least one contaminating host cell protein; (b) contacting the at least one sample with a reaction solution (comprising a hydrophilic substrate) to form a reaction mixture, wherein the reaction solution comprises: (i) a pH of about pH 4 to about pH 5; 8 buffer, (ii) a hydrophilic substrate, wherein the substrate is a saturated unbranched fatty acid (C6-C12) ester of 1-hydroxypyrene-3,6,8-trisulfonic acid or a salt thereof (substrate HPTS ester), and (iii) an optional non-buffered salt; (c) incubating the sample and substrate in the reaction mixture; and (d) detecting the carboxylesterase activity of at least one contaminating host cell protein by measuring the hydrolysis of the substrate HPTS ester and detecting the fluorescence intensity of the released chromophore 1-hydroxypyrene-3,6,8-trisulfonic acid or a salt thereof (HPTS); optionally, while incubating the sample and substrate in the reaction mixture according to step (c), measuring the hydrolysis by detecting the fluorescence intensity of the released chromophore HPTS over a period of time. In certain embodiments, the sample and substrate in the reaction mixture are incubated for any period of time between 2 minutes and 5 hours, 2 minutes and 3 hours, 2 minutes and 2 hours, or 2 minutes and 0.5 hours; and / or the reaction mixture has a volume of 300 μl or less. According to this method, multiple reaction mixtures can be analyzed in parallel, preferably in a volume of 300 μl or less.

[0011] Preferably, the fluorescence of the released chromophore HPTS is determined using an excitation wavelength in the range of 401-405 nm and an emission wavelength in the range of 510-516 nm. In a preferred embodiment, the substrate HPTS ester is selected from 1-octanoyloxy-pyrene-3,6,8-trisulfonic acid or its salt (OPTS), 1-nonanoyloxy-pyrene-3,6,8-trisulfonic acid or its salt and 1-decanoyloxy-pyrene-3,6,8-trisulfonic acid or its salt. In a more preferred embodiment, the substrate HPTS ester is selected from 1-octanoyloxy-pyrene-3,6,8-trisulfonic acid trisodium salt (OPTS), 1-nonanoyloxy-pyrene-3,6,8-trisulfonic acid trisodium salt and 1-decanoyloxy-pyrene-3,6,8-trisulfonic acid trisodium salt. Preferably, the substrate HPTS ester is used in the reaction mixture at a final concentration of 50 μM or less or preferably 30 μM or less.

[0012] In a preferred embodiment, the method further comprises (bi) contacting at least one sample of step (a) comprising the recombinant protein of interest produced in eukaryotic cells in cell culture and at least one contaminating host cell protein in a separate reaction setup with a reaction solution comprising a lipophilic substrate to form a reaction mixture, wherein the reaction solution comprises: (i) a pH of about pH 4 to about pH 8, (ii) a lipophilic substrate comprising the chromophore 4-methylumbelliferone (4-MU) in the form of a 4-MU ester, wherein the 4-MU ester is a saturated unbranched fatty acid (C6-C16) 4-MU ester, (iii) optionally a non-buffering salt, and (iv) a non-denaturing detergent without an ester bond, wherein the detergent is a non-ionic or zwitterionic detergent, (ci) incubating the sample and substrate in the reaction mixture of step (bi); and (di) detecting the lipase activity of at least one contaminating host cell protein by measuring the hydrolysis of the substrate 4-MU ester and detecting the fluorescence intensity of the released chromophore 4-MU; optionally measuring the hydrolysis by detecting the fluorescence intensity of the released chromophore 4-MU over a period of time while incubating the sample and substrate in the reaction mixture according to step (ci).

[0013] The lipophilic substrate is preferably selected from 4-methylumbelliferyl octanoate, 4-methylumbelliferyl nonanoate, 4-methylumbelliferyl decanoate (4-MUD), 4-methylumbelliferyl undecanoate and 4-methylumbelliferyl dodecanoate. Micelle formation improves lipase activity and dissolution of lipophilic substrates. Therefore, according to the present invention, the detergent used in the reaction solution containing the lipophilic substrate has a final concentration in the reaction mixture that is higher than its critical micelle concentration in the reaction mixture. In certain embodiments, the detergent is selected from CHAPS, CHAPSO and Zwittergent, preferably CHAPS. In the case where the detergent is CHAPS, it is preferably provided in the reaction mixture at a final concentration of about 8mM to about 20mM, preferably about 8mM to about 15mM, and more preferably about 10mM. In certain embodiments, the detergent is not polyethylene glycol tert-octylphenyl ether (Triton X-100) nor polyethylene glycol nonylphenyl ether (NP-40).

[0014] The buffer used in the method of the present invention (using hydrophilic and / or lipophilic substrates) may comprise one or more buffer substances selected from the group consisting of formic acid, acetic acid, lactic acid, citric acid, malic acid, maleic acid, glycine, glycylglycine, succinic acid, TES (2-{[tris(hydroxymethyl)methyl]amino}ethanesulfonic acid), MOPS (3-(N-morpholino)propanesulfonic acid), PIPES (piperazine-N,N'-bis(2-ethanesulfonic acid)), MES (2-(N-morpholino)ethanesulfonic acid), Tris base, Tris, Bis-Tris, B-Tris. is-Tris-propane, Bicine (N,N-bis(2-hydroxyethyl)glycine), HEPES (4-2-hydroxyethyl-1-piperazineethanesulfonic acid), TAPS (3-([tris(hydroxymethyl)methyl]amino}propanesulfonic acid), Tricine (N-tris(hydroxymethyl)methylglycine), Na2HPO4 and NaH2PO4. In certain embodiments, the buffer has a pH of about 5 to about 7.5, preferably the buffer has a pH of about 5.5 to about 7.0. The buffer can also be a multi-component buffer having a buffer range of at least about pH 5 to at least about pH 7.5, preferably at least about pH 4 to at least about pH 8.

[0015] Optionally, the non-buffering salt can be selected from NaCl, KCl and CaCl2, preferably, the non-buffering salt is NaCl or KCl. In addition, the non-buffering salt can have a concentration of about 100mM to about 200mM in the reaction mixture, preferably about 130mM to about 170mM, more preferably about 140mM to about 150mM. In certain embodiments, the ionic strength of the non-buffering salt is about 200mM or less in the reaction mixture, preferably about 150mM or less in the reaction mixture; and / or the cumulative ionic strength of the buffer and the non-buffering salt in the reaction mixture is about 450mM or less in the reaction mixture, preferably about 400mM or less, more preferably about 350mM or less.

[0016] According to certain embodiments, at least one sample is a cell culture fluid (HCCF) harvested, an in-process control (IPC) sample, a UF / DF filtrate, a bulk drug sample or a drug product sample. In a preferred embodiment, the recombinant protein of interest is produced in a CHO cell, and at least one contaminating host cell protein is a CHO host cell protein (CHOP). According to the present invention, the recombinant protein of interest is not a carboxylesterase or lipase and / or an enzyme with carboxylesterase or lipase activity. Preferably, the recombinant protein of interest is selected from an antibody, an antibody fragment, an antibody-derived molecule and a fusion protein.

[0017] The present invention further provides a method for making a recombinant protein of interest, comprising the steps of: (i) culturing eukaryotic cells expressing the recombinant protein of interest in cell culture; (ii) harvesting the recombinant protein of interest; (iii) purifying the recombinant protein of interest; and (iv) optionally formulating the recombinant protein of interest into a pharmaceutically acceptable formulation suitable for administration; and (v) obtaining at least one sample comprising the recombinant protein of interest in steps (ii), (iii) and / or (iv); wherein the method further comprises detecting carboxylesterase activity in the sample comprising the recombinant protein of interest and at least one contaminating host cell protein, comprising: (a) providing at least one sample obtained in step (v), the sample comprising the recombinant protein of interest produced in eukaryotic cells in cell culture and at least one contaminating host cell protein; (b) contacting the at least one sample with a reaction solution comprising a hydrophilic substrate to form a reaction mixture, wherein the reaction solution comprises: (i) a pH of about pH 4 to about pH 5; 8 buffer, (ii) a hydrophilic substrate, wherein the substrate is a saturated unbranched fatty acid (C6-C12) ester of 1-hydroxypyrene-3,6,8-trisulfonic acid or a salt thereof (substrate HPTS ester), and (iv) optionally a non-buffering salt; (c) incubating the sample and the substrate in the reaction mixture; and (d) detecting the carboxylesterase activity of at least one contaminating host cell protein by measuring the hydrolysis of the substrate HPTS ester and detecting the fluorescence intensity of the released chromophore HPTS; wherein the method optionally further comprises detecting the lipase activity in the sample, which comprises (bi) contacting at least one sample of step (a) in a separate reaction setup comprising the recombinant protein of interest produced in a eukaryotic cell and at least one contaminating host cell protein with a reaction solution comprising the lipophilic substrate to form a reaction mixture, wherein the reaction solution comprises: (i) a pH of about pH 4 to about pH 5 8, (ii) a lipophilic substrate comprising the chromophore 4-methylumbelliferone (4-MU) in the form of a 4-MU ester, wherein the 4-MU ester is a saturated unbranched fatty acid (C6-C16) 4-MU ester, (iii) optionally a non-buffering salt, and (iv) a non-denaturing detergent without an ester bond, wherein the detergent is a non-ionic or zwitterionic detergent, (ci) incubating the sample and the substrate in the reaction mixture; (di) detecting the lipase activity of at least one contaminating host cell protein by measuring the hydrolysis of the 4-MU ester and detecting the fluorescence intensity of the released chromophore 4-MU; optionally, while incubating the sample and the substrate in the reaction mixture according to step (c) or (ci), measuring the hydrolysis by detecting the fluorescence intensity of the released chromophore HPTS and / or 4-MU over a period of time.

[0018] The method for manufacturing according to the present invention may further comprise obtaining at least one sample comprising the recombinant protein of interest in step (ii), wherein the sample is a harvested cell culture fluid (HCCF) or a cell lysate; in step (iii), wherein the sample is an in-process control (IPC) sample; and / or in step (iv), wherein the sample is a UF / DF sample, a drug substance sample or a drug product sample. In a preferred embodiment, the method comprises obtaining in step (iii) at least one sample comprising the recombinant protein of interest produced in eukaryotic cells in cell culture and at least one contaminating host cell protein, comprising obtaining at least one sample before and after affinity chromatography, before and after acid treatment, before and after depth filtration, and / or before and after ion exchange chromatography, preferably anion exchange chromatography or cation exchange chromatography.

[0019] In yet another aspect, the present invention relates to a kit for determining contaminating carboxylesterase activity and / or lipase activity in a sample comprising a recombinant protein of interest, the kit comprising: (i) a buffer having a pH of about pH 4 to about pH 8; and (ii) a hydrophilic substrate and a lipophilic substrate, wherein (a) the hydrophilic substrate is a saturated unbranched fatty acid (C6-C12) ester of 1-hydroxypyrene-3,6,8-trisulfonic acid or a salt thereof (substrate HPTS ester); and (b) the lipophilic substrate comprises the chromophore 4-methylumbelliferone (4-MU) in the form of a 4-MU ester, wherein the 4-MU ester is a saturated unbranched fatty acid (C6-C16) 4-MU ester (substrate 4-MU ester); and optionally (iii) a non-buffering salt; and / or (iv) a non-denaturing detergent having no ester bond, wherein the detergent is a nonionic or zwitterionic detergent.

[0020] In certain embodiments, the hydrophilic substrate HPTS ester in the kit is selected from 1-octanoyloxy-pyrene-3,6,8-trisulfonic acid or its salt (OPTS), 1-nonanoyloxy-pyrene-3,6,8-trisulfonic acid or its salt and 1-decanoyloxy-pyrene-3,6,8-trisulfonic acid or its salt (e.g., 1-octanoyloxy-pyrene-3,6,8-trisulfonic acid trisodium salt (OPTS), 1-nonanoyloxy-pyrene-3,6,8-trisulfonic acid trisodium salt or 1-decanoyloxy-pyrene-3,6,8-trisulfonic acid trisodium salt); and / or the lipophilic substrate 4-MU ester is selected from 4-methylumbelliferyl octanoate, 4-methylumbelliferyl nonanoate, 4-methylumbelliferyl decanoate (4-MUD), 4-methylumbelliferyl undecanoate and 4-methylumbelliferyl dodecanoate. The kit according to the present invention may further comprise one or more microtiter plates having 96 wells or a multiple of 96 wells.

[0021] In a further aspect, the present invention relates to the use of a hydrophilic substrate HPTS ester or a hydrophilic substrate HPTS ester and a lipophilic substrate 4-MU ester as substrate for detecting carboxylesterase activity or carboxylesterase and lipase activity (respectively) of a contaminating host cell protein in a sample in an assay, wherein the sample comprises a recombinant protein of interest produced in eukaryotic cells in cell culture, preferably wherein the recombinant protein is produced in CHO cells and the at least one contaminating host cell protein is a CHO host cell protein (CHOP), wherein the hydrophilic substrate is a saturated unbranched fatty acid (C6-C12) ester of 1-hydroxypyrene-3,6,8-trisulfonic acid or a salt thereof (substrate HPTS ester), and wherein the lipophilic substrate is a saturated unbranched fatty acid (C6-C16) 4-MU ester.

[0022] In yet another aspect, the present invention relates to the use of a hydrophilic substrate HPTS ester as a substrate for detecting carboxylesterase activity of at least one contaminating host cell protein in a sample in an assay, wherein the sample comprises a recombinant protein of interest produced in eukaryotic cells in cell culture, preferably wherein the recombinant protein is produced in CHO cells and the at least one contaminating host cell protein is a CHO host cell protein (CHOP), wherein the hydrophilic substrate is a saturated unbranched fatty acid (C6-C12) ester of 1-hydroxypyrene-3,6,8-trisulfonic acid or a salt thereof (substrate HPTS ester). BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 : (A) Schematic representation of esterase families potentially involved in polysorbate degradation. (B) Schematic representation of esterases detected by the novel OPTS assay and the 4-MUD assay, showing small overlap and otherwise complementary groups of carboxylesterases and lipases. (C) Schematic representation of the hydrolysis reaction of the substrate 4-methylumbelliferyl decanoate (4-MUD) to form the fluorophore 4-methylumbelliferyl (4-MU). (D) Schematic representation of the hydrolysis reaction of the substrate 1-octanoyloxy-pyrene-3,6,8-trisulfonic acid (OPTS) trisodium salt to form the fluorophore 1-hydroxypyrene-3,6,8-trisulfonic acid (HPTS) trisodium salt.

[0024] Figure 2 : (A) Spectra of HPTS at excitation wavelength 300-500 nm at emission wavelength 520 nm for pH values ​​4-8 (top), and at emission wavelength 420-620 nm at excitation wavelength 415 for pH = 5.5 (bottom). (B) Calibration curves for different pH values ​​(4-8) for HPTS concentration range of 1.46-3000 nM (top), calibration line for pH = 7 for HPTS concentration range of 93.75-6000 nM (bottom).

[0025] Figure 3 : Kinetic measurements of 25 μM OPTS solutions with AMT buffer pH=5.5 (filled squares) and pH=8 (open triangles) over a two hour period

[0026] Figure 4 :With 1mg*mL -1 Kinetic measurements of a reaction mixture of PPL, 25 μM OPTS and AMT (pH=7) for 30 min.

[0027] Figure 5 : (A) in the presence or absence of 10 mM CHAPS for 30 min, and (B) in the presence of Tween 20 at the indicated concentrations with 1 mg*mL -1 Kinetic measurements of the reaction mixture of PPL, 25 μM OPTS and AMT (pH=7).

[0028] Figure 6 : (A) 1 mg*mL in 150 mM Tris, 0.25% (w / v) Triton X-100, 0.125% (w / v) gum arabic, pH=8 (TTG buffer as described for the esterase activity assay of WO 2020 / 047416 A2) and AMT buffer at pH=8 in the presence or absence of 10 mM CHAPS for 30 min. -1 Kinetic measurements of reaction mixtures of PPL, 100 μM OPTS.

[0029] Figure 7 : Kinetic measurements of 9 different antibody preparations using 25 μM OPTS, AMT buffer (pH = 5.5), 75 μL of each antibody solution (labeled 1-9) and 300 μL of aqueous H 2 O. Kinetics were recorded at 25° C. for 30 minutes with n = 2 measurements, results represent arithmetic means and error bars represent maximum errors.

[0030] Figure 8 : Kinetic measurements of 9 different antibody preparations using 30 μM 4-MUD substrate, AMT buffer (pH = 5.5), 75 μL of each antibody solution (labeled 1-9) and 300 μL of aqueous H 2 O. Kinetics were recorded at 25° C. for 30 minutes, where n = 2, the results represent the arithmetic mean and the error bars represent the maximum error.

[0031] Fig. 9: Kinetic measurements using 25 μM OPTS (filled squares) or 30 μM 4-MUD substrate (open circles), AMT buffer (pH = 5.5), 75 μL of the respective antibody solution (labeled 1-9) and 300 μL of aqueous H 2 O. Kinetics were recorded at 25° C. for 30 minutes, where n = 2, the results represent the arithmetic mean and the error bars represent the maximum error.

[0032] Fig.10 : Kinetic measurements using 30 μM 4-MUD substrate, AMT buffer (pH = 5.5), 75 μL of the respective antibody solution (labeled 1-9), 10 μM orlistat (squares) or 1 mM PMSF (circles) or 10 mM EDTA (triangles) and 300 μL aqueous H 2 O. Kinetics were recorded at 25° C. for 30 min, where n = 2, results represent the arithmetic mean and error bars represent the maximum error.

[0033] Fig.11 : Kinetic measurements of lipase using 25 μM OPTS (filled squares) or 30 μM 4-MUD substrate (open circles), AMT (pH = 5.5), without and with different inhibitors (10 μM orlistat, 1 mM PMSF, 10 mM EDTA) and 300 μL aqueous H2O. Final lipase concentration was 0.007 mg*mL -1 The activities correspond to the mean activity units and the error bars correspond to the maximum error for n=2 measurements.

[0034] Fig.12 : At the indicated pH and 0.007 mg*mL -1 pH profile of lipase measured in 25 μM OPTS solution with AMT (filled squares) and 30 μM 4-MUD substrate solution (open circles) under lipase. The activity in units is plotted against the pH of the buffer and the error corresponds to the maximum error at n=2 measurements.

[0035] Fig.13 : pH profiles of Ab9 preparations measured in 25 μM OPTS solution with AMT (filled squares) and 30 μM 4-MUD substrate solution (open circles) at the indicated pH. The activity in units is plotted against the pH of the buffer and the error corresponds to the maximum error of n=2 measurements.

[0036] Fig.14: (A) pH profiles of the two preparations measured in 25 μM OPTS solution with AMT (filled squares) and 30 μM 4-MUD substrate solution (open circles) at the indicated pH, and (B) scaled to measurements using 4-MUD substrate. The activity in units is plotted against the pH of the buffer, and the error corresponds to the maximum error of n=2 measurements.

[0037] Fig.15 : (A) pH profiles of the five formulations measured in 25 μM OPTS solution with AMT (filled squares) and 30 μM 4-MUD substrate solution (open circles) at the indicated pH, and (B) scaled to measurements using coumarin substrate. The activity in units is plotted against the pH of the buffer, and the error corresponds to the maximum error of n=2 measurements. DETAILED DESCRIPTION

[0038] The term "comprises" or "comprising" means "including but not limited to". The term is intended to be open-ended to specify the presence of any stated features, elements, integers, steps, or components, but does not exclude the presence or addition of one or more other features, elements, integers, steps, components, or groups thereof. Therefore, the term "comprising" includes the stricter terms "consisting of" and "consisting essentially of". In addition, the singular and plural forms are not used in a limiting manner. As used herein, the singular forms "a", "an", and "the" designate both the singular and the plural, unless explicitly stated to specify only the singular.

[0039] As used herein, the term "sample" refers to any sample comprising a recombinant protein of interest, wherein the recombinant protein of interest is produced in eukaryotic cells in cell culture: at least one sample can be, for example, a harvested cell culture fluid (HCCF) or cell lysate, an in-process control (IPC) sample, an ultrafiltration / diafiltration sample (UF / DF sample), a bulk drug (also referred to as bulk drug) sample or a drug product sample comprising a recombinant protein of interest, such as an antibody, an antibody fragment, an antibody-derived molecule or a fusion protein (e.g., an Fc fusion protein). As used herein, the recombinant protein of interest contained in the sample is not a carboxylase or lipase and / or does not comprise a carboxylase or lipase activity. Therefore, any carboxylase or lipase activity detected in the sample is a contaminating carboxylase or lipase activity and / or is derived from at least one contaminating protein having a carboxylase or lipase activity, such as a host cell protein (HCP) derived from a eukaryotic cell.

[0040] As used herein, the term "contaminating" or "contamination" refers to the presence of unwanted and / or unintended substances, such as endogenous proteins produced by host cells, also referred to as host cell proteins, in particular host cell proteins with esterase (carboxylesterase or lipase) activity, which are present only as trace components compared to the recombinant protein of interest, such as an antibody or antibody-like compound. In the context of the present invention, hydrolytic activity and in particular lipase or carboxylesterase activity is undesirable due to its polysorbate degradation potential, which may be co-purified with the recombinant protein of interest. This applies in particular to the final formulated protein preparation, which advantageously contains only less than 1% (w / w), preferably less than 0.1% (w / w), more preferably less than 0.01% (w / w) of such unwanted factors compared to the total protein content.

[0041] As used herein, the term "lipase activity" refers to a substance, typically the activity of a protein (enzyme) that catalyzes the hydrolysis of ester bonds in lipids such as fatty acid esters. As used herein, the term "carboxylesterase activity" refers to a substance, typically the activity of a protein (enzyme) that catalyzes the hydrolysis of ester bonds in carboxylates. Lipase or carboxylesterase is a hydrolase that splits esters into acid and alcohol in a chemical reaction with water, also referred to as hydrolysis. Many lipases and carboxylesterases belong to the carboxylester hydrolase category (EC3.1.1). Although carboxylesterases constitute a separate carboxylesterase class (EC 3.1.1.1), the lipase may be, but is not limited to, a triacylglycerol lipase (EC 3.1.1.3), a phospholipase A2 (EC 3.1.1.4), a lysophospholipase (EC 3.1.1.5), an acylglycerol lipase (EC 3.1.1.23), a galactolipase (EC 3.1.1.26), a phospholipase A1 (EC 3.1.1.32), a lipoprotein lipase (EC 3.1.1.34), or a hormone-sensitive lipase (EC 3.1.1.79); a phosphodiesterase (EC 3.1.4) such as a phospholipase D (EC 3.1.4.4), a phosphoinositide phospholipase C (EC 3.1.4.11), a glycosylphosphatidylinositol phospholipase D (EC 3.1.4.2), a phosphoinositide phospholipase C (EC 3.1.4.12), a phosphoinositide phospholipase C (EC 3.1.4.13), a phosphoinositide phospholipase D (EC 3.1.4.24), a phosphoinositide phospholipase C (EC 3.1.4.14), a phosphoinositide phospholipase C (EC 3.1.4.15), a phosphoinositide phospholipase C (EC 3.1.4.16), a phosphoinositide phospholipase C (EC 3.1.4.17), a phosphoinositide phospholipase C ( 3.1.4.50) or N-acetylphosphatidylethanolamine hydrolyzing phospholipase D (EC 3.1.4.54); or glycosphingolipid deacylase (EC 3.5.1.69).

[0042] Carboxylesterase or lipase in the context of the present invention are such pollutants, which are undesirable and often difficult to remove, and may or may not mediate polysorbate degrading enzyme activity. Contaminating carboxylesterase may be immunogenic and / or have polysorbate degrading activity, such as sialyl acetylesterase (SIAE). Carboxylesterase prefers hydrophilic substrates, and therefore uses substrate HPTS ester assay to detect. Similarly, contaminating lipase may be immunogenic and / or have polysorbate degrading activity, such as PLBL2, LPL, LPLA2, PLA2G7, LYPLA2 and LIPA. Lipase prefers lipophilic substrates, and therefore uses substrate 4-methylumbelliferone (4-MU) ester assay to detect. As used herein, the term "hydrolase activity" is a more general term that includes lipase and carboxylesterase activity, but also refers to the hydrolysis of compounds other than lipids or carboxyl esters, such as thioester hydrolases (EC 3.1.2), such as palmitoyl protein thioesterase 1 (PPT1), which can also be detected by the combined assays disclosed herein.

[0043] The terms "protein" and "amino acid sequence" or "polypeptide" are used interchangeably and refer to polymers of amino acids of any length. These terms also include proteins that are post-translationally modified by reactions including, but not limited to, glycosylation, acetylation, phosphorylation, glycation, or protein processing. Modifications and changes can be made in the structure of a polypeptide, such as fusions to other proteins, amino acid sequence substitutions, deletions, or insertions, while the molecule maintains its biological functional activity. For example, certain amino acid sequence substitutions can be made in a polypeptide or its underlying nucleic acid coding sequence, and a protein with the same properties can be obtained.

[0044] As used herein, the term "recombinant protein" refers to a protein generated by recombinant techniques such as molecular cloning, and may also be referred to as a recombinant protein of interest. As used herein, a recombinant protein is a protein of interest in a sample such as to be purified. Recombinant techniques bring together genetic materials from multiple sources or produce sequences that are not naturally occurring. Recombinant proteins are generally based on sequences from cells or organisms or different species different from the receptor host cells (such as CHO cells or HEK 293 cells) used to produce proteins in cell culture, or based on artificial sequences such as fusion proteins. In the context of the present invention, a recombinant protein is a protein of interest, preferably a therapeutic protein, such as an antibody, an antibody fragment, an antibody-derived molecule (such as scFv, bispecific or multispecific antibodies) or a fusion protein (such as Fc fusion protein). Therefore, in one embodiment, a recombinant protein is selected from an antibody, an antibody fragment, an antibody-derived molecule and a fusion protein.

[0045] As used herein, the term "eukaryotic cell" refers to a cell having a nucleus within a nuclear envelope, and includes animal cells, human cells, plant cells and yeast cells. In the present invention, "eukaryotic cell" particularly encompasses mammalian cells, such as cells derived from Chinese hamster ovary (CHO) cells or HEK293 cells, and yeast cells. As used herein, mammalian cells refer to cells of mammalian origin, particularly cell lines. In the present invention, "mammalian cell" particularly encompasses human or rodent cells, and in most cases refers to Chinese hamster ovary (CHO) cells or derivatives thereof. Cells as mentioned herein are cells maintained in culture, and are not related to primary cells, but are cell lines or cell line-derived cells, i.e. immortalized cells.

[0046] The term "drug substance (DS)" refers to an active pharmaceutical ingredient (API) formulated with excipients. The API mediates therapeutic efficacy in vivo, in contrast to excipients that aid in the delivery of the API. In the case of biotherapeutics, API formulated with excipients generally means the API in the final formulation buffer at a concentration of at least the highest concentration used in the final dosage form, also referred to as the drug product.

[0047] As used herein, the term "drug product", abbreviated as DP, refers to the final marketed dosage form of the drug substance, such as a tablet or capsule, or in the case of a biologic, usually an injectable solution in an appropriate container such as a vial or syringe. The drug product may also be in lyophilized form.

[0048] As used herein, the term "polysorbate 20" refers to a nonionic polysorbate-type detergent, which is a lauric acid ester of sorbitol and its anhydride copolymerized with approximately 20 moles of ethylene oxide per mole of sorbitol and sorbitan (polyoxyethylene (20) sorbitan monolaurate; CAS number: 9005-64-5). It is also known as Tween 20. Its stability and relative nontoxicity allow it to be used as a surfactant / detergent and emulsifier in a variety of household and scientific analyses. Polysorbate 20 can be used as a washing reagent in immunoassays, Western blotting and ELISA. It can further be used in pharmacological applications, such as in pharmaceutical formulations, particularly for biologics, such as antibodies and Fc fusion proteins. In particular, it helps prevent nonspecific antibody binding.

[0049] As used herein, the term "polysorbate 80" refers to a nonionic polysorbate-type detergent which is a mixture of partial esters of fatty acids, primarily oleic acid, and sorbitol and its anhydride ethoxylated with approximately 20 millimoles of ethylene oxide for each mole of sorbitol and sorbitan (polyoxyethylene (20) sorbitan monooleate, CAS No. 9005-65-6). It is also known as Tween 80 and has similar uses to polysorbate 20.

[0050] As used herein, the term "therapeutic protein" refers to a protein that can be used in the medical treatment of humans and / or animals. These include, but are not limited to, antibodies, growth factors, coagulation factors, vaccines, interferons, hormones, and fusion proteins.

[0051] As used herein, the term "production" relates to the production of a recombinant protein of interest, preferably a therapeutic protein, in eukaryotic cells, preferably yeast cells or mammalian cells in cell culture. Those skilled in the art know how to use fermentation to produce recombinant proteins in cells. The production of recombinant proteins includes culturing eukaryotic cells expressing the recombinant protein of interest in cell culture. Cultivating eukaryotic cells expressing the recombinant protein in cell culture includes maintaining the eukaryotic cells in a suitable culture medium and under conditions that allow growth and / or protein production / expression. The recombinant protein can be produced by fed-batch or continuous cell culture. Therefore, the eukaryotic cells can be cultured in fed-batch or continuous cell culture or a combination thereof, preferably in fed-batch cell culture.

[0052] As used herein, the term "expressing a recombinant protein" refers to cells comprising a DNA sequence encoding a recombinant protein of interest, which is transcribed and translated into a protein sequence including post-translational modifications, i.e. resulting in the production of the recombinant protein in cell culture.

[0053] As used herein, the term "about" refers to a 10% variation of the specified value, for example, about 50% carries a variation of 45 to 55%.

[0054] As used herein, the term "detecting the carboxylesterase activity of at least one contaminating host cell protein" refers to the step of measuring the hydrolysis of the substrate HPTS ester by detecting the fluorescence intensity of the released chromophore 1-hydroxypyrene-3,6,8-trisulfonic acid or its salt (HPTS). Therefore, "detecting the carboxylesterase activity of at least one contaminating host cell protein by measuring the hydrolysis of the substrate HPTS ester and detecting the fluorescence intensity of the released chromophore 1-hydroxypyrene-3,6,8-trisulfonic acid or its salt (HPTS)" is used synonymously herein with "detecting the carboxylesterase activity of at least one contaminating host cell protein comprises (or by / via) measuring the hydrolysis of the substrate HPTS ester by detecting the fluorescence intensity of the released chromophore 1-hydroxypyrene-3,6,8-trisulfonic acid or its salt (HPTS). The step of measuring the hydrolysis of the substrate HPTS ester is understood to be performed by detecting the fluorescence intensity of the released chromophore 1-hydroxypyrene-3,6,8-trisulfonic acid or its salt (HPTS).

[0055] Similarly, as used herein, the term "detecting the lipase activity of at least one contaminating host cell protein" refers to and is performed by the step of measuring the hydrolysis of the substrate 4-MU ester by detecting the fluorescence intensity of the released chromophore 4-MU. Therefore, "detecting the lipase activity of at least one contaminating host cell protein by measuring the hydrolysis of the substrate 4-MU ester and detecting the fluorescence intensity of the released chromophore 4-MU" is used synonymously herein with "detecting the carboxylesterase activity of at least one contaminating host cell protein includes (or by / via) measuring the hydrolysis of the substrate 4-MU ester by detecting the fluorescence intensity of the released chromophore 4-MU." The step of measuring the hydrolysis of the substrate 4-MU ester is understood to be performed by detecting the fluorescence intensity of the released chromophore 4-MU.

[0056] Method for detecting carboxylesterase activity of contaminating host cell proteins

[0057] The present invention relates to a method for detecting carboxylesterase activity of a contaminating host cell protein in a sample comprising a recombinant protein of interest produced in a eukaryotic cell in cell culture (an in vitro method), comprising (a) providing at least one sample comprising a recombinant protein of interest produced in a eukaryotic cell in cell culture and at least one contaminating host cell protein; (b) contacting the at least one sample with a reaction solution (comprising a hydrophilic substrate) to form a reaction mixture, wherein the reaction solution comprises: (i) a pH of about pH 4 to about pH 5; 8, (ii) a hydrophilic substrate, wherein the substrate is a saturated unbranched fatty acid (C6-C12) ester of 1-hydroxypyrene-3,6,8-trisulfonic acid or a salt thereof (substrate HPTS ester), and (iii) optionally a non-buffering salt; (c) incubating the sample and the substrate in the reaction mixture; (d) detecting the carboxylesterase activity of at least one contaminating host cell protein by measuring the hydrolysis of the substrate HPTS ester and detecting the fluorescence intensity of the released chromophore 1-hydroxypyrene-3,6,8-trisulfonic acid or a salt thereof (HPTS); optionally, while incubating the sample and the substrate in the reaction mixture according to step (c), measuring the hydrolysis by detecting the fluorescence intensity of the released chromophore HPTS over a period of time. Therefore, in step (d), detecting the carboxylesterase activity of at least one contaminating host cell protein comprises measuring the hydrolysis of the substrate HPTS ester by detecting the fluorescence intensity of the released chromophore 1-hydroxypyrene-3,6,8-trisulfonic acid or its salt (HPTS), optionally while incubating the sample and substrate in the reaction mixture according to step (c), measuring the hydrolysis by detecting the fluorescence intensity of the released chromophore HPTS over a period of time. The reaction solution used in the method of the present invention is an aqueous reaction solution. It will be appreciated by those skilled in the art that in step (b), a portion of at least one sample is used for each reaction mixture. Further, more than one sample and / or more than one portion of at least one sample can be analyzed in parallel. These more than one sample and / or more than one portion can be analyzed under the same conditions or under separate conditions, such as analyzing a portion of at least one sample (or its duplicate or triplicate) at different pH values, respectively. The method is particularly suitable for small volume and high throughput analysis. Therefore, multiple reaction mixtures can be analyzed in parallel, for example, in a microtiter plate having 96 wells or multiples of 96 wells. Preferably, each reaction mixture has a volume of 300 μl or less. Preferably, each reaction mixture has a volume of 300 μl or less.

[0058] Determination read out can be as fast as 20 minutes or even faster.Therefore, in certain embodiments, make the sample and substrate incubation in the reaction mixture less than 5 hours, less than 3 hours, less than 2 hours or less than 0.5 hours.In order to obtain enough data points, it is suggested to make the sample and substrate incubation in the reaction mixture at least 1 minute, at least 2 minutes or at least 5 minutes.Therefore, the sample and substrate in the reaction mixture can be incubated for 2 minutes to 5 hours, 2 minutes to 3 hours, 2 minutes to 2 hours or any time period between 2 minutes to 0.5 hours, or 2 minutes to less than 5 hours, less than 3 hours, less than 2 hours or less than any time period between 0.5 hours.In certain embodiments, parallel analysis multiple reaction mixtures, such as 12 or more, 24 or more, 36 or more, 72 or more or 96 or more, and / or reaction mixture has 300 μ l or less volume.At least one sample can be HCCF, process control (IPC) sample, UF / DF sample, bulk drug or drug product.According to the present invention, the recombinant protein of interest in the sample is not carboxylesterase and / or does not comprise carboxylesterase activity.

[0059] In certain embodiments, the fluorescence of the released chromophore HPTS is determined using an excitation wavelength in the range of 401-405 nm and an emission wavelength in the range of 510-516 nm, preferably an excitation wavelength in the range of 402-404 nm and an emission wavelength in the range of 510-514 nm, more preferably an excitation wavelength of 403 nm and an emission wavelength of 512 nm.

[0060] Hydrolysis can be stopped at a certain time point before the fluorescence intensity of the released chromophore HPTS is detected. Alternatively and preferably, the fluorescence intensity of the released chromophore HPTS can be detected in real time without stopping the hydrolysis of the hydrophilic substrate HPTS ester. In certain embodiments, the fluorescence intensity of the released chromophore HPTS is detected without stopping the hydrolysis of the hydrophilic substrate HPTS ester. In certain embodiments, while the sample and substrate in the reaction mixture are incubated according to step (c), the fluorescence intensity of the released chromophore HPTS is measured over a period of time.

[0061] The hydrophilic substrate comprising the chromophore HPTS is in the form of a saturated unbranched fatty acid (C6 to C12) HPTS ester, wherein the acyl chain of the saturated unbranched fatty acid has C6 to C12 carbon atoms. As used herein, the abbreviation "HTPS" refers to 1-hydroxypyrene-3,6,8-trisulfonic acid or a salt thereof, preferably the trisodium salt. Similarly, as used herein, the abbreviation "substrate HPTS ester" refers to a saturated unbranched fatty acid (C6-C12) ester of 1-hydroxypyrene-3,6,8-trisulfonic acid or a salt thereof, preferably the trisodium salt. As used herein, the abbreviation "OPTS" refers to 1-octanoyloxy-pyrene-3,6,8-trisulfonic acid or a salt thereof, preferably the trisodium salt. Saturated unbranched fatty acids (C6 to C12) HPTS esters, such as 1-octanoyloxy-pyrene-3,6,8-trisulfonic acid (OPTS) trisodium salt, are hydrolyzed in the presence of carboxylesterase to saturated unbranched fatty acids (C6 to C12), such as octanoic acid and -hydroxypyrene-3,6,8-trisulfonic acid (HPTS) trisodium salt as shown below:

[0062]

[0063] The substrate mimics the key features of polysorbates, namely the fatty acid ester bond and the long acyl chain. Polysorbate 20 is an ester of lauric acid (a saturated unbranched fatty acid). In contrast, polysorbate 80 is an ester of oleic acid (an unsaturated fatty acid). The hydrophilic substrate is an ester of 1-hydroxy pyrene-3,6,8-trisulfonic acid or its salt with a saturated unbranched fatty acid (C6-C12) (substrate HPTS ester). Autohydrolysis increases for substrate HPTS esters with shorter saturated unbranched fatty acids (<C6), while substrate HPTS esters with longer saturated unbranched fatty acids (>C12) become more lipophilic and thus become less favorable substrates for carboxylesterase. Thus, the substrate HPTS esters are selected from 1-hexanoyloxy-pyrene-3,6,8-trisulfonic acid, 1-heptanoyloxy-pyrene-3,6,8-trisulfonic acid, 1-octanoyloxy-pyrene-3,6,8-trisulfonic acid (OPTS), 1-nonanoyloxy-pyrene-3,6,8-trisulfonic acid, 1-decanoyloxy-pyrene-3,6,8-trisulfonic acid, 1-undecanoyloxy-pyrene-3,6,8-trisulfonic acid, 1-dodecanoyloxy-pyrene-3,6,8-trisulfonic acid and their salts. Preferably, the substrate HPTS ester is a C8-C10 ester, such as selected from 1-octanoyloxy-pyrene-3,6,8-trisulfonic acid or its salt (OPTS), 1-nonanoyloxy-pyrene-3,6,8-trisulfonic acid or its salt and 1-decanoyloxy-pyrene-3,6,8-trisulfonic acid or its salt. The salt can be any salt, such as sodium salt or potassium salt. In a preferred embodiment, the chromophore 1-hydroxy pyrene-3,6,8-trisulfonic acid or its salt is trisodium 1-hydroxy pyrene-3,6,8-trisulfonate, and the substrate HPTS esters are selected from trisodium 1-hexanoyloxy-pyrene-3,6,8-trisulfonate, trisodium 1-heptanoyloxy-pyrene-3,6,8-trisulfonate, trisodium 1-octanoyloxy-pyrene-3,6,8-trisulfonate (OPTS), trisodium 1-nonanoyloxy-pyrene-3,6,8-trisulfonate, trisodium 1-decanoyloxy-pyrene-3,6,8-trisulfonate, trisodium 1-undecanoyloxy-pyrene-3,6,8-trisulfonate and trisodium 1-dodecanoyloxy-pyrene-3,6,8-trisulfonate, more preferably selected from trisodium 1-octanoyloxy-pyrene-3,6,8-trisulfonate (OPTS), trisodium 1-nonanoyloxy-pyrene-3,6,8-trisulfonate and trisodium 1-decanoyloxy-pyrene-3,6,8-trisulfonate.

[0064] The substrate HPTS ester is a hydrophilic substrate and is thus readily soluble in water. Organic solvents and detergents tend to interfere with the determination of the hydrophilic substrate HPTS ester and / or quench the chromophore HPTS. Thus, the hydrophilic substrate HPTS ester is preferably dissolved in an aqueous solution, such as water or an aqueous buffer, more preferably an aqueous solution that does not contain DMSO or DMF.

[0065] In the method of the present invention, suitable hydrophilic substrate concentration (in the reaction mixture) can be about 1 μM to about 1 mM. Preferably, the hydrophilic substrate HPTS ester is used in the reaction mixture at a final concentration of 50 μM, more preferably 30 μM or less. Therefore, in certain embodiments, the substrate is provided in the reaction mixture at a final concentration of about 1 μM to about 1 mM, preferably about 1 μM to about 300 μM, preferably about 1 μM to about 50 μM, preferably about 1 μM to about 30 μM, more preferably about 3 μM to about 30 μM. In certain embodiments, the substrate is provided as a stock solution in an aqueous solution. As used herein, the term "aqueous solution" means a water-based solution, such as water or a buffer (such as a buffer used in a reaction solution), preferably without an organic solvent. The stock solution is added to a reaction mixture of about 1% to about 10% (v / v).

[0066] Furthermore, it is essential that the reaction solution comprising the substrate HPTS ester does not contain detergents above its critical micelle concentration (CMC), preferably, the reaction solution comprising the substrate HPTS ester does not contain detergents (e.g., nonionic detergents, nonionic detergents or zwitterionic detergents). This particularly includes non-denaturing detergents (nonionic or zwitterionic detergents) without ester bonds as described herein, as well as ethoxylates and / or detergents containing polyethylene glycol groups (e.g., tert-octylphenyl ether of ethylene glycol (Triton X-100, CAS No. 9002-93-1) and / or polyethylene glycol nonylphenyl ether (NP-40, CAS No. 9016-45-9)) and / or aromatic rings. Thus, in a specific embodiment, the reaction solution does not contain detergents, such as Triton X-100, NP-40 or CHAPS, in particular not above the respective CMC. Preferably, the detergent is not present in the reaction solution or the reaction solution comprising the hydrophilic substrate and the reaction mixture at or above its critical micelle concentration (CMC), more preferably, the detergent is not present in the reaction solution or the reaction solution and the reaction mixture. In certain preferred embodiments, the reaction solution as used in the method according to the present invention does not contain a detergent, and the reaction solution comprises (i) a buffer, (ii) a hydrophilic substrate and optionally (iii) a non-buffered salt. It will be appreciated by those skilled in the art that since the sample to be analyzed may contain a detergent, the reaction mixture may contain a small amount of detergent after the reaction solution is contacted with the sample. The hydrophilic substrate HPTS ester assay is intended for in-process control samples for the manufacture of recombinant proteins of interest as a rapid high-throughput assay for purification sequence development and optimization. Most in-process control samples do not contain detergents, such as polysorbate 20 or polysorbate 80. Samples that may contain detergents are primarily final drug substances and may be harvested cell culture fluid (HCCF) due to defoamers. However, given the high hydrolase activity in HCCF (before purification), the sample needs to be diluted and thus the potential defoamer to a concentration that does not interfere with the assay. Therefore, the final reaction mixture (containing the sample and reaction solution of the hydrophilic substrate) may contain low concentrations of polysorbate 20 or 80 derived from the sample as described herein. With respect to the final product, most drug substance samples have a non-critical polysorbate concentration (e.g., about 50 μg / ml polysorbate 20 or less) after dilution in the reaction mixture. Alternatively, UF / DF samples (i.e., before polysorbate addition) can be used to determine the hydrolytic activity, if desired.The concentration of polysorbate 20 or polysorbate 80 in the reaction mixture should preferably be below the CMC and / or not exceed about 100 μg / ml, preferably about 75 μg / ml, more preferably about 50 μg / ml for polysorbate 20 (or not exceed about 60 μg / ml, preferably about 50 μg / ml, preferably about 30 μg / ml, more preferably about 20 μg / ml for polysorbate 80). However, we also note in this context that the assay is particularly useful for high-throughput analysis of IPC samples in small volumes for process optimization, which samples typically do not contain polysorbates.

[0067] It was further observed that histidine may inhibit the method according to the present invention using the hydrophilic substrate HPTS ester. Histidine is often used in the formulation buffer. In the case where histidine is present in the sample, dialysis should be performed before the method according to the present invention to remove histidine from the sample. Methods for preparative dialysis are well known in the art. For example, the antibody solution can be dialyzed against 500 volumes of 0.002% (w / v) NaCl solution using a pre-wetted dialysis cassette, accompanied by gentle stirring, and the 0.002% (w / v) NaCl solution is replaced at least once. Each dialysis step is maintained for about 1-2 hours. It was found that a histidine concentration of less than 200 μM is acceptable. Therefore, in one embodiment, a sample containing a protein of interest is dialyzed until a concentration of less than 200 μM histidine is reached. An alternative method is to use a dextran-epichlorohydrin copolymer Column (size exclusion chromatography) or affinity chromatography. In certain embodiments, a sample comprising a recombinant protein of interest produced in eukaryotic cells in cell culture and at least one contaminating host cell protein contains less than 200 μM histidine, preferably less than 100 μM histidine. Thus, for the final product, if desired, the drug substance sample can be dialyzed, or a UF / DF sample (i.e., before histidine (and polysorbate) is added) can be used to determine the hydrolysis activity. However, we note in this context that the assay is particularly useful for high-throughput analysis of small volumes of IPC samples for process optimization, which do not typically contain histidine.

[0068] The method according to the invention may further comprise analyzing at least one sample using a lipophilic substrate 4-MU ester. Thus, the method may further comprise detecting lipase activity in a sample comprising a recombinant protein of interest produced in eukaryotic cells and at least one contaminating host cell protein. In certain embodiments, the method according to the invention further comprises (bi) contacting at least one sample of the recombinant protein of interest produced in eukaryotic cells in cell culture and at least one contaminating host cell protein of step (a) in a separate reaction setup with a reaction solution comprising a lipophilic substrate to form a reaction mixture, wherein the reaction solution comprises: (i) a pH of about pH 4 to about pH 5; 8, (ii) a lipophilic substrate comprising the chromophore 4-methylumbelliferone (4-MU) in the form of a 4-MU ester, wherein the 4-MU ester is a saturated unbranched fatty acid (C6-C16) 4-MU ester (substrate 4-MU ester), (iii) optionally a non-buffering salt, and (iv) a non-denaturing detergent without an ester bond, wherein the detergent is a non-ionic or zwitterionic detergent, (ci) incubating the sample in the reaction mixture of step (bi) with the substrate; (di) detecting the lipase activity of at least one contaminating host cell protein by measuring the hydrolysis of the substrate 4-MU ester and detecting the fluorescence intensity of the released chromophore 4-MU; optionally measuring the hydrolysis by detecting the fluorescence intensity of the released chromophore 4-MU over a period of time while incubating the sample in the reaction mixture with the substrate according to step (ci). Therefore, in step (di), detecting the lipase activity of at least one contaminating host cell protein comprises measuring the hydrolysis of substrate 4-MU ester by detecting the fluorescence intensity of the released chromophore 4-MU, optionally while incubating the sample and substrate in the reaction mixture according to step (ci), measuring the hydrolysis by detecting the fluorescence intensity of the released chromophore 4-MU over a period of time. It will be appreciated by those skilled in the art that in step (bi), a portion of at least one sample is used for each reaction mixture. More specifically, in step (b), a portion of at least one sample is used for each reaction mixture, and in step (bi), another portion of at least one sample is used for each reaction mixture. Further, more than one sample can be analyzed in parallel and / or more than one portion (or fraction) of at least one sample can be analyzed in parallel using substrate HPTS ester and optional substrate 4-MU ester. These more than one sample and / or more than one portion can be analyzed under the same conditions or under separate conditions, such as analyzing a portion (or duplicate or triplicate) of at least one sample each at different pH values. This method is particularly suitable for small volume and high throughput analysis. Thus, multiple reaction mixtures can be analyzed in parallel, for example in microtiter plates having 96 wells or multiples of 96. Preferably, each reaction mixture has a volume of 300 μl or less.

[0069] Use hydrophilic substrate HPTS ester and add lipophilic substrate 4-MU ester to analyze at least one sample and broaden the enzyme capture spectrum by potentially relating to the mensuration of polysorbate degradation.Hydrophilic substrate and hydrophilic substrate complement each other by detecting the enzyme (for example lipase) with hydrolysis activity and suitable lipophilic substrate specificity and the enzyme (for example carboxylesterase) with hydrolysis activity and suitable hydrophilic substrate specificity.These substrates are expected to use the same at least one sample in parallel or subsequent use.It will be appreciated by those skilled in the art that the first part of at least one sample contacts with the reaction solution as defined in step (b), and the second part of at least one sample contacts with the reaction solution as defined in step (bi).

[0070] As used herein, the term "different reaction set-up" refers to a separate reaction that is different from the reaction using a reaction solution comprising a hydrophilic substrate HPTS ester because it uses a reaction solution comprising a lipophilic substrate 4-MU ester and is carried out in different containers or wells (i.e., physically separated). Different reaction set-ups are usually carried out using the same at least one sample, more precisely each using a portion of the same at least one sample for contacting and analysis. The buffer (and optional non-buffering salt) used in the reaction solution comprising the hydrophilic substrate and the reaction solution comprising the lipophilic substrate is preferably the same. Therefore, the reaction solution comprising the hydrophilic substrate and the reaction solution comprising the lipophilic substrate are the same, except for the substrate and detergent that are only present in the reaction solution comprising the lipophilic substrate.

[0071] The substrate comprising chromophore 4-MU is in the form of saturated unbranched fatty acid (C6 to C16) 4-MU ester, wherein the acyl chain of the saturated unbranched fatty acid has C6 to C16 carbon atom. The key feature of this substrate imitation polysorbate, i.e. fatty acid ester bond and long acyl chain. Polysorbate 20 is the ester of fatty acid lauric acid (a kind of saturated unbranched fatty acid). In contrast, polysorbate 80 is the ester of fatty acid oleic acid (a kind of unsaturated fatty acid). The fluorescence of released chromophore 4-MU is suitable for detecting fluorescence in a fluorescence spectrometer or microplate spectrophotometer. In certain embodiments, the fluorescence of released chromophore 4-MU is determined using an excitation wavelength within the range of 330-340nm and an emission wavelength of 450nm.

[0072] Unsaturated fatty acids are bulkier than saturated fatty acids due to the double bonds, and further, branched fatty acids are bulkier than unbranched fatty acids. The lipase activity and / or carboxylesterase activity in a sample containing a recombinant protein of interest may be mediated by one or more lipases and / or carboxylases and may differ between various recombinant proteins of interest, such as individual antibodies (see Fig. 9). Therefore, in most cases, the contaminating host cell protein with lipase activity and / or carboxylase activity is unknown, and may be a mixture of more than one protein. Especially, many lipases, such as triacylglycerol lipase, can be in open state or closed state, and the active site is isolated from the solvent by the part, valve or lid of the polypeptide chain. Therefore, the active site of many lipases is similar to the inside of a cavity or barrel, which most likely determines substrate specificity. Therefore, compared with, for example, oleic acid esters with longer and unsaturated acyl chains, the esters of the saturated unbranched fatty acids (little fatty acids of volume) of the lipophilic substrate 4-MU ester of the medium length (C6-C16) used in the method of the present invention are likely to capture a wider zymogram. Similarly, compared with the fatty acids with longer and / or unsaturated acyl chains, the esters of the saturated unbranched fatty acids (little fatty acids of volume) of the hydrophilic substrate HTPS ester of the medium length (C6-C12) used in the method of the present invention are likely to capture a wider zymogram. Preferably, the substrates HTPS ester and / or 4-MU ester, alone or in combination, capture an equal or broader enzyme spectrum than PS20 or PS80.

[0073] Further, fatty acid esters with shorter acyl chains provide better solubility in water-based (aqueous) reaction mixtures compared to fatty acid esters with longer chain lengths. Thus, more substrates can be used in the assay mixture. More specifically, it was found that the solubility of substrate 4-MU esters becomes strongly limited at C16 or longer chain lengths. Although substrate HPTS esters are generally more water-soluble, without being bound by theory, increasing the chain length to more than C12 makes the substrate more lipophilic, which may convert the zymogram into more enzymes with more lipophilic substrate specificity, such as lipases, thereby reducing the width of the combined zymogram of substrate HPTS esters and substrate 4-MU esters.

[0074] In addition, it was found for the substrate 4-MU ester that decanoate (4-MUD) provides better resistance to autohydrolysis than, for example, butyrate (4-MUB). It was found that chain lengths up to C5 strongly increase autohydrolysis. It is reported that the C10 fatty acid in 4-MUD is optimal for use in the assay (WO 2022 / 049294 A1), but slightly longer or shorter saturated unbranched fatty acid esters, such as saturated unbranched fatty acids (C6 to C16) 4-MU esters or more preferably saturated unbranched fatty acids (C8 to C12) 4-MU esters can also be used similarly in the method according to the invention. Similar observations about autohydrolysis were also made for the hydrophilic substrate HPTS ester. Therefore, the hydrophilic substrate HPTS ester used in the method according to the invention has an acyl chain of saturated unbranched fatty acids from C6 to C12 carbon atoms.

[0075] When lipophilic 4-MU ester is used in addition in the method according to the present invention, it has the acyl chain of saturated unbranched fatty acid of C6 to C16 carbon atoms. More preferably, fatty acid is medium chain fatty acid, and 4-MU ester is saturated unbranched fatty acid (C8 to C12) 4-MU ester. In certain embodiments, lipophilic substrate is selected from 4-methylumbelliferyl caprylate, 4-methylumbelliferyl nonanoate, 4-methylumbelliferyl decanoate (4-MUD), 4-methylumbelliferyl undecanoate and 4-methylumbelliferyl dodecanoate. In certain preferred embodiments, lipophilic substrate is selected from 4-methylumbelliferyl caprylate, 4-methylumbelliferyl decanoate (4-MUD) and 4-methylumbelliferyl dodecanoate. In a more preferred embodiment, substrate is 4-MUD. The lipophilic substrate 4-MU ester is typically dissolved in an organic solvent, such as dimethyl sulfoxide (DMSO) or dimethylformamide (DMF), preferably DMSO, as a stock solution (e.g., a stock solution at 100x relative to the concentration in the reaction mixture). In certain embodiments, the lipophilic substrate is provided as a stock solution dissolved in an organic solvent selected from DMSO or DMF, preferably DMF.

[0076] Suitable lipophilic substrate concentrations (in the reaction mixture) in the present invention may be from about 1 μM to about 1 mM. Thus, in certain embodiments, the substrate is provided in the reaction mixture at a final concentration of from about 1 μM to about 1 mM, preferably from about 1 μM to about 300 μM, preferably from about 1 μM to about 30 μM, more preferably from about 3 μM to about 30 μM. In certain embodiments, the substrate is provided as a stock solution in an organic solvent, wherein the stock solution is added at about 1% to about 5% (v / v) of the reaction mixture.

[0077] The method according to certain embodiments comprises contacting at least one sample with a reaction solution comprising a non-denaturing detergent without ester bonds, wherein the detergent is a non-ionic or zwitterionic surfactant (also referred to herein as a "non-denaturing non-ionic or zwitterionic detergent without ester bonds"). As used herein, the term "detergent" refers to a surface-active compound capable of forming micelles. Detergents may also be referred to herein as surfactants. Detergents are amphiphilic, i.e., they contain both a hydrophobic group (tail) and a hydrophilic group (head). Detergents are typically organic compounds. In an aqueous phase, detergents form aggregates, such as micelles, in which the hydrophobic tail forms the core of the aggregate and the hydrophilic head is in contact with the surrounding aqueous liquid. Therefore, the hydrophobic tail (also referred to as the hydrophobic hydrocarbon portion) has a certain length to form micelles. Therefore, as used herein, detergents do not cover organic solvents, such as ethanol or dimethyl sulfoxide (DMSO). The tails of most detergents are typically composed of one or more hydrocarbon chains, which may be branched, linear or aromatic. Detergents may contain one or more hydrophobic tails, preferably, the detergent contains one hydrophobic chain (single-tailed detergent). Detergents are usually classified according to the hydrophilic head group. Nonionic detergents do not have charged groups in their head, ionic detergents carry a net positive charge (cation) or negative charge (anion), and zwitterionic detergents contain two oppositely charged groups. Therefore, nonionic or zwitterionic detergents do not carry a net charge at the hydrophilic head group and are therefore milder in nature. In addition, in many detergents, the hydrophobic tail is connected to the hydrophilic head via an ester bond, such as in PS20 or PS80. In addition, nonionic or zwitterionic detergents are non-denaturing detergents. As used herein, the term "non-denaturing detergent" refers to the effect of the detergent on protein structure. Non-denaturing detergents do not disrupt protein-protein interactions, especially interactions of water-soluble proteins.

[0078] Detergents containing ester bonds are potential substrates for lipases or carboxylesterases and may therefore interfere with the assay. Furthermore, denaturation of proteins with lipase activity should be avoided and thus interference with the lipase activity in the sample should be avoided. Therefore, the detergent to be used in the method according to the invention is a non-denaturing detergent without ester bonds, wherein the detergent is a nonionic or zwitterionic detergent. Examples of suitable non-denaturing zwitterionic detergents are, but are not limited to, 3-[(3-cholamidopropyl)dimethylammonium]-1-propanesulfonate (CHAPS), 3-([3-cholamidopropyl)dimethylammonium]-2-hydroxy-1-propanesulfonate (CHAPSO), CHAPS analogs (e.g., Big CHAP N,N-bis-(3-D-glucosamidopropyl)deoxycholamid), Zwittergent (various lengths, e.g., n-dodecyl-N,N-dimethyl-3-ammonium-1-propanesulfonate (Zwittergent 3-12)), and 3-[N,N-dimethyl(3-palmitamidopropyl)ammonium]-propanesulfonate or other aminosulfobetaine detergents. Examples of suitable non-denaturing nonionic detergents are, but are not limited to, pyranoside detergents (e.g., octyl β-D-glucopyranoside (OGP), nonyl β-D-glucopyranoside, dodecyl β-D-maltopyranoside (DDM) or octyl β-D-thioglucopyranoside), polyoxyethylene (23) lauryl ether (Brij 35) or other polyoxyethylene ethers; saponins (e.g., digitonin), octylphenoxypolyethoxyethanol (IGEPAL CA-630), poloxamer 188, 338, 407 or tergitol. In certain embodiments, the non-denaturing detergent (nonionic or zwitterionic detergent) having no ester linkage is not ethoxylated and / or does not contain a polyethylene glycol group and / or does not contain an aromatic ring. In certain embodiments, the non-denaturing nonionic or zwitterionic detergent without an ester bond is not octoxynol-9, specifically not polyethylene glycol tert-octylphenyl ether (Triton X-100, CAS No. 9002-93-1) and / or polyethylene glycol nonylphenyl ether (NP-40, CAS No. 9016-45-9). In a preferred embodiment, the detergent is a non-denaturing detergent without an ester bond, wherein the detergent is a non-ionic or zwitterionic detergent, more preferably the detergent is a non-denaturing detergent (non-ionic or zwitterionic detergent) selected from the following: CHAPS (CAS No. 75621-03-3), CHAPSO (CAS No. 82473-24-3), Zwittergent (e.g. Zwittergent 3-12; CAS No. 14933-08-5) and saponin (CAS No. 8047-15-2), preferably CHAPS. None of these exemplary suitable detergents exhibit ester bonds or acyl chains and are therefore not substrates for lipases.These detergents do not compete with the substrate and therefore do not affect the sensitivity of the assay. In addition, the presence of the detergent mediates the solubility of the substrate in water at the concentrations used. One skilled in the art will know how to identify further suitable non-denaturing nonionic or zwitterionic detergents that do not have an ester bond by determining their effect on 4-MU ester hydrolysis under the assay conditions.

[0079] The presence of detergents (e.g., 10 mM CHAPS) has been shown to increase lipase activity and thus improve the sensitivity of the assay. Without being bound by theory, it is hypothesized that the detergent creates an environment that promotes lipase activity by allowing rearrangement and opening of the lid or valve, which has been described as covering the active site (Grochulski P, Li Y, Schrag JD et al., Protein Sci 1994; 3: 82-91 and Grochulski P, Bouthillier F, Kazlauskas RJ et al., Biochemistry 1994; 33: 3494-500). To achieve this effect, the detergent should be above its critical micelle concentration (CMC).

[0080] Thus, according to the present invention, the non-denaturing detergent (nonionic or zwitterionic) has a final concentration in the reaction mixture that is higher than its critical micelle concentration (CMC) in the reaction mixture. CMC represents an important physicochemical property of a given detergent in aqueous solution. Micelles are spherical aggregates whose hydrocarbon groups are largely not in contact with water. As used herein, the term "critical micelle concentration" or "CMC" refers to the concentration of the detergent at which micelles are formed (i.e., the maximum monomer concentration), and can be determined according to methods known in the art. For example, a suitable method for determining CMC is the fluorescent micelle assay (FMA), which uses the fluorescent hydrophobic dye N-phenyl-1-naphthylamine (NPN) to be distributed into the detergent micelles. NPN shows a low fluorescence quantum yield in an aqueous environment, which increases in a more hydrophobic environment such as the core of a micelle. This assay was originally developed for CMC determination and is also used to determine the polysorbate content in a biopharmaceutical as in the examples. An alternative approach utilizing the fluorescence enhancement of 1,6-diphenyl-1,3,5-hexatriene (DPH) after micellization was described by Chattopadhyay and Harikumar (FEBS Letters 391 (1996) 199-202).

[0081] The CMC for the detergent can be derived from the literature and is, for example, about 6 mM for CHAPS, about 8 mM for CHAPSO and about 2-4 mM for Zwittergent 3-12. In certain embodiments, the non-denaturing zwitterionic detergent is CHAPS and is provided in the reaction mixture at a final concentration of about 8 mM to about 20 mM, preferably about 8 mM to about 15 mM, more preferably about 10 mM. In other embodiments, the non-denaturing zwitterionic detergent is CHAPSO and is provided in the reaction mixture at a final concentration of about 10 mM to about 20 mM, preferably about 10 mM to about 15 mM. In yet another embodiment, the non-denaturing zwitterionic detergent is Zwittergent 3-12 and is provided in the reaction mixture at a final concentration of about 4 mM to about 10 mM, preferably about 6 mM to about 8 mM. In yet another embodiment, the non-denaturing non-ionic detergent is saponin and is provided in the reaction mixture at a final concentration of 0.001% to 0.01% (w / v).

[0082] Hydrolysis can be stopped at some time point before the fluorescence intensity of the released chromophore 4-MU is detected. Alternatively and preferably, the fluorescence intensity of the released chromophore 4-MU can be detected in real time without stopping the hydrolysis of the lipophilic substrate 4-MU ester. In certain embodiments, the fluorescence intensity of the released chromophore 4-MU is detected without stopping the hydrolysis of the lipophilic substrate 4-MU ester. In certain embodiments, while the sample and substrate in the reaction mixture are incubated according to step (ci), the hydrolysis is measured by detecting the fluorescence intensity of the released chromophore 4-MU over a period of time.

[0083] Real-time detection allows measurement of hydrolysis over a period of time, and therefore specific reaction rates can be determined. In the method according to the present invention, the hydrolysis of the substrate HPTS ester or 4-MU ester in the reaction mixture generally follows a pseudo-zero-order reaction rate. Therefore, real-time detection of fluorescence allows measurement in a time frame with a pseudo-zero-order reaction rate. Therefore, in certain embodiments, the fluorescence intensity of the released chromophore HPTS or 4-MU is detected over a period of time, and the pseudo-zero-order reaction rate is followed. Optionally, the reaction mixture that does not meet the requirements of the pseudo-zero-order reaction rate is excluded from the analysis. The pseudo-zero-order reaction rate can be evaluated by linear regression analysis. Preferably, the sample is run at least in triplicate, and in the case where they do not meet the pseudo-zero-order reaction rate, for example, due to bubbles in the hole, etc., individual reaction mixtures are excluded from the analysis to eliminate outliers. The elimination of outliers as described strongly increases the sensitivity of the assay. The calibration curve using a defined concentration of HPTS or 4-MU can be used to calculate the hydrolysis rate (e.g., nmol / s). The calibration curve with a known HPTS or 4-MU concentration further allows the determination and comparison of the reaction speed at different pH values.

[0084] As used herein, the term "reaction rate" refers to the speed at which an enzyme converts a substrate into at least one product over a specific period of time. In some reactions, the rate is apparently independent of the reactant concentrations. This means that the rate of the equation is equal to the rate constant k of the reaction, and is referred to as a zero-order reaction. Zero-order kinetics is always an artifact of the conditions under which the reaction is carried out. For this reason, reactions that follow zero-order kinetics are often referred to as pseudo-zero-order reactions.

[0085] The method according to the present invention may further comprise the steps of: determining the hydrolysis rate by detecting the fluorescence intensity of the released chromophore HPTS or 4-MU as relative fluorescence units (RFU), and determining the amount (mol / s) of the released chromophore HPTS or 4-MU by comparing it with a calibration curve generated by using a defined concentration of HPTS or 4-MU. Typically, activity is measured by the release of HPTS or 4-MU in nmol / minute. Alternatively or in addition, the relative value can be calculated by comparison with an internal standard, such as another sample or preferably a commercially available lipase, such as porcine pancreatic lipase (PPL) (or a commercially available crude extract comprising PPL), which serves as a positive control.

[0086] Incubation of sample and substrate in reaction mixture allows the potential presence of at least one contaminating host cell protein with carboxylesterase activity to hydrolyze substrate HPTS ester, and in the separated sample, the potential presence of at least one contaminating host cell protein with lipase activity to hydrolyze substrate 4MU ester. Incubation is generally a few minutes to a few hours. In one embodiment, while incubating the sample and substrate in the reaction mixture according to step (c) or (ci) respectively, i.e., in real time during incubation, hydrolysis is measured by detecting the fluorescence intensity of the released chromophore HPTS or 4-MU over a period of time. Due to the sensitivity of the assay, detection is generally started immediately after step (b) or (bi) respectively. Incubation and therefore the detection time may depend on the lipase activity present in the sample, and are generally not more than 5 hours, preferably not more than 3 hours. In certain embodiments, the sample and substrate incubation in the reaction mixture is less than 5 hours, less than 3 hours, less than 2 hours, less than 1 hour or less than 0.5 hour. In order to obtain enough data points, it is recommended to incubate the sample and substrate in the reaction mixture for at least about 1 minute, at least about 2 minutes or at least about 5 minutes. Thus, the sample and substrate in the reaction mixture may be incubated for any period of time between 2 minutes and 5 hours, 2 minutes and 3 hours, 2 minutes and 2 hours, or 2 minutes and 0.5 hours, or any period of time between about 2 minutes and less than 5 hours, less than 3 hours, less than 2 hours, or less than 0.5 hours. Preferably, the sample and substrate in the reaction mixture are incubated for between 20 minutes and 2 hours at a temperature of about 25°C. Since the reaction temperature affects the reaction time, the reaction temperature should be kept constant during the measurement, for example, between 20-37°C, preferably between 22-28°C, and more preferably at a constant temperature between 24-26°C. In one embodiment, the sample and substrate in the reaction mixture are incubated at a constant temperature between 20-37°C, preferably between 22-28°C, more preferably between 24-26°C for less than 5 hours, less than 3 hours, less than 2 hours or less than 1 hour, or between 20-37°C, preferably between 22-28°C, more preferably between 24-26°C, for any period of time between 2 minutes to 5 hours, 2 minutes to 3 hours, 2 minutes to 2 hours or 2 minutes to 0.5 hours, or about 2 minutes to less than 5 hours, less than 3 hours, less than 2 hours or less than 1 hour. In certain embodiments, the reaction mixture has a volume of 300 μl or less. In certain embodiments, multiple reaction mixtures, such as 12 or more, 24 or more, 36 or more, 72 or more, or 96 or more, are analyzed in parallel, preferably with a volume of 300 μl or less.

[0087] The reaction solution used in the method according to the present invention (for both the hydrophilic substrate HPTS ester and the lipophilic substrate 4-MU ester) further comprises a buffer having a pH of about pH 4 to about pH 8. Preferably, the method is carried out using a buffer having a pH of about pH 5 to about pH 7.5, more preferably about pH 5.5 to about pH 7.5. It will be appreciated by those skilled in the art that the pH of the buffer is within its buffering range when used in the method of the present invention. In principle, any buffer known in the art may be used provided that it has a buffering range within about pH 4 to about pH 8. The buffer may comprise a single buffer substance or may be a multi-component buffer. Multi-component buffers generally have a wider buffering range. For example, the buffer may comprise one or more buffer substances selected from the group consisting of formic acid, acetic acid, lactic acid, citric acid, malic acid, maleic acid, glycine, glycylglycine, succinic acid, TES (2-{[tris(hydroxymethyl)methyl]amino}ethanesulfonic acid), MOPS (3-(N-morpholino)propanesulfonic acid), PIPES (piperazine-N,N'-bis(2-ethanesulfonic acid)), MES (2-(N-morpholino)ethanesulfonic acid), Tris base, Tris, Bis-Tris, Bis-Tris-propane, Bicine (N,N-bis(2-hydroxyethyl)propane), Preferably, the buffer is a phosphate buffer (Na2HPO4 and NaH2PO4), a Tris buffer or a HEPES buffer. In certain embodiments, the buffer has a concentration of about 50 to 400 mM, preferably about 50 to 300 mM, and more preferably about 50 to 200 mM.

[0088] The buffer may further be a multi-component buffer comprising more than one buffer material with overlapping buffer ranges, so as to have a wider buffer range. The buffer may for example comprise two, three, four, five or more buffer materials, preferably two or more buffer materials, more preferably three or more buffer materials. For example, the multi-component buffer may comprise two to four buffer materials, three to four buffer materials, more preferably three buffer materials. In certain embodiments, the multi-component buffer comprises at least three buffer materials with overlapping buffer ranges, preferably comprises at least one of Tris, MES and / or acetic acid, preferably acetic acid, MES and Tris in a ratio of 1:1:2.

[0089] Since the assay has been shown to be sensitive to ionic strength, it is important for designing a suitable multi-component buffer that it not only contains buffer substances with overlapping buffering ranges, but also that the buffer only moderately changes (less than 15%, preferably even less than 10%) the ionic strength at different pH (range pH 4-8) (Ellis KJ, Morrisson JF, 1982. Methods in Enzymology, 87: 405-426). For example, an AMT buffer containing acetic acid, MES and Tris allows the use of buffers at different pHs with only moderate effects on ionic strength, for example, to identify conditions, including pH conditions that reduce hydrolytic activity. The buffer further allows measurements to be made at the pH of the sample to determine the lipase activity under specific conditions present in the sample, as well as to compare the lipase activity under different conditions during the purification process. The assay allows the sensitivity to be further increased by measuring the sample at the optimal pH.

[0090] Thus, multi-component buffers as disclosed herein allow for the use of buffers with variable pH from at least about pH 5 to at least about pH 7.5, or from at least about pH 4 to at least about pH 8. Alternatively or in addition, the use of buffers with different pH values ​​between about pH 4 and about pH 8 affects the ionic strength of the buffer by less than 15%, preferably less than 10%, or even less than 7.5% or less than 5%, such as from 0% to less than 15%, from 0% to less than 10%, from 0% to less than 7.5% or from 0% to less than 5%, or such as from 2% to less than 15%, from 2% to less than 10%, from 2% to less than 7.5% or from 2% to less than 5%. In one embodiment, the use of buffers having different pH values ​​between about pH 4 and about pH 8 has an effect on the ionic strength of the buffer of less than 15%, preferably less than 10%, or even less than 7.5% or less than 5%, such as from 0% to less than 15%, from 0% to less than 10%, from 0% to less than 7.5%, or from 0% to less than 5%, or such as from 2% to less than 15%, from 2% to less than 10%, from 2% to less than 7.5%, or from 2% to less than 5%. The use of multi-component buffers as disclosed herein further allows the pH of the buffer to be adjusted to the pH of the sample (without changing the buffer composition of the buffer). The use of multi-component buffers as disclosed herein further allows the pH of the buffer to be adjusted to a value close to the optimum for at least one contaminating protein having lipase activity (thereby increasing the sensitivity of the method) and / or to compare and identify conditions that reduce hydrolytic activity.

[0091] The reaction solution may further comprise a non-buffering salt. In the present invention, any salt that dissociates in water and has no buffering effect is suitable for adjusting the ionic strength of the reaction solution. Examples of suitable salts are NaCl, KCl or CaCl 2 . In a certain example of the present invention, the non-buffering salt is selected from NaCl, KCl and CaCl 2 , preferably, the non-buffering salt is NaCl or KCl.

[0092] The concentration of optional non-buffered salt can be in the range of about 100mM to about 200mM. In a certain embodiment of the present invention, non-buffered salt has about 100mM to about 200mM in the reaction mixture, preferably about 130mM to about 170mM, more preferably about 140mM to about 150mM concentration. However, due to the negative impact on lipase activity, the ionic strength in the reaction mixture should not exceed a certain value. For example, the ionic strength of optional non-buffered salt is preferably about 200mM or lower, about 190mM or lower, about 180mM or lower, about 170mM or lower, about 160mM or lower, or about 150mM or lower in the reaction mixture, for example, about 100mM to about 200mM in the reaction mixture, preferably about 130mM to about 170mM, more preferably about 140mM to about 150mM. In certain embodiments, the cumulative ionic strength of the buffer and non-buffered salt in the reaction mixture is no more than about 450mM. Accordingly, the cumulative ionic strength of the buffer and non-buffer salt in the reaction mixture can be about 450mM or less, about 400mM or less, about 380mM or less, about 360mM or less, or about 350mM or less. For example, the cumulative ionic strength of the buffer and non-buffer salt in the reaction mixture can be about 150mM to about 450mM or less, about 150mM to about 400mM or less, about 150mM to about 380mM or less, about 150mM to about 360mM or less, or about 150mM to about 350mM or less.

[0093] The buffer according to the step (b) of the method according to the invention can be identical or can be different with the buffer according to the step (bi) of the method according to the invention. In a preferred embodiment, the buffer according to the step (b) of the method according to the invention is identical with the buffer according to the step (bi) of the method according to the invention. Therefore, buffer components, concentration and pH value or pH range are identical. This is also applicable to optional non-buffered salts, its presence and its concentration. This excludes other differences except substrate specificity when detecting carboxylesterase activity and lipase activity.

[0094] The method according to the invention is suitable for detecting fluorescence (preferably, λ for HPTS) in a fluorescence spectrometer or a microplate spectrophotometer. Ex 401-405nm, λ Em510-516nm, and λ for 4-MU Ex 330-340nm, λ Em 450nm). Therefore, the reaction mixture is included (and preferably mixed) in a cuvette or microtiter plate, preferably at least 96-well microtiter plates for measurement. Therefore, the method according to the present invention is particularly suitable for high-throughput analysis and / or automated analysis of samples. In certain embodiments, in the method according to the present invention, at least 2, 3, 4, 5, 10 or more samples are analyzed simultaneously. Further, each sample is preferably measured at least in triplicate. Therefore, preferably, a microtiter plate with 96 holes or multiples of 96 holes is used to carry out the method according to the present invention. Microtiter plates are not only used to measure the hydrolysis in step (d) or step (di), but also used to contact at least one sample with the reaction solution in step (d) or step (di), and in step (c) or step (ci), the sample in the reaction mixture is incubated with substrate. Therefore, in certain embodiments, the sample is contacted, incubated and measured in the form of a microtiter plate with 96 holes or multiples of 96 holes.

[0095] In certain embodiments, the sample is provided at about 30% (v / v) or less, preferably about 25% (v / v) or less of the reaction mixture. Therefore, the sample can be provided at about 20% (v / v) to about 30% (v / v) of the reaction mixture, preferably at about 20% (v / v) to about 25% (v / v) of the reaction mixture. Optionally, the sample can be pre-diluted. At least one sample containing the recombinant protein of interest can be a harvested cell culture fluid (HCCF) or cell lysate, an in-process control (IPC) sample, a bulk drug sample or a drug product sample, preferably an IPC sample, a bulk drug sample or a drug product sample. Preferably, contacting at least one sample with the reaction solution to form a reaction mixture includes mixing at least one sample with the reaction solution to obtain a homogenous reaction mixture. This is preferably accomplished by first adding a smaller volume (usually a sample), and secondly adding a larger volume (usually a reaction solution). Preferably, the components of the reaction solution are added as a main mixture, wherein the main mixture can be prepared as a concentrate, which is diluted to a working concentration before adding the sample.

[0096] At least one sample can be a harvested cell culture fluid (HCCF) or cell lysate, an in-process control (IPC) sample, a UF / DF sample, a bulk drug sample or a drug product sample. The recombinant protein of interest in the sample for detecting carboxylesterase activity and optional lipase activity is preferably a therapeutic protein, such as an antibody, an antibody fragment, an antibody-derived molecule, a fusion protein (such as an Fc fusion protein), a growth factor, a cytokine or a hormone, preferably an antibody, an antibody fragment, an antibody-derived molecule or an Fc fusion protein. Therefore, the recombinant protein of interest is preferably a secretory protein. As used herein, the term "harvested cell culture fluid" or "HCCF" refers to the cell culture supernatant after harvesting, i.e., after separation from the cells. According to the present invention, the recombinant protein of interest in the sample for detecting lipase activity is not a carboxylesterase or a lipase and / or does not contain a carboxylesterase or a lipase activity. Therefore, any carboxylesterase or lipase activity detected in at least one sample is a contaminating carboxylesterase or a lipase activity and / or is derived from at least one contaminating host cell protein with a carboxylesterase or a lipase activity, such as a CHO host cell protein (CHOP) derived from a CHO cell. In addition, the recombinant protein of interest in the sample according to the method of the present invention is not an esterase or hydrolase and / or does not comprise an esterase or hydrolase activity. In certain embodiments, the recombinant protein of interest is produced in CHO cells, and at least one contaminating host cell protein is a CHO host cell protein (CHOP).

[0097] Therefore, the method according to the present invention can advantageously be used to detect carboxylesterase or lipase activity by measuring hydrolysis in a sample comprising an antibody, an antibody fragment, an antibody-derived molecule or a fusion protein (e.g., an Fc fusion protein). Typically, antibodies are monospecific, but antibodies can also be multispecific. Therefore, the method according to the present invention can be used for samples comprising monospecific antibodies, multispecific antibodies or fragments thereof, preferably antibodies (monospecific), bispecific antibodies, trispecific antibodies or fragments thereof, preferably antigen-binding fragments thereof. Exemplary antibodies within the scope of the present invention include, but are not limited to, anti-CD2, anti-CD3, anti-CD20, anti-CD22, anti-CD30, anti-CD33, anti-CD37, anti-CD40, anti-CD44, anti-CD44v6, anti-CD49d, anti-CD52, anti-EGFR1 (HER1), anti-EGFR2 (HER2), anti-GD3, anti-IGF, anti-VEGF, anti-TNFα, anti-IL2, anti-IL-5R, anti-IL-36R or anti-IgE antibodies, and are preferably selected from anti-CD20, anti-CD33, anti-CD37, anti-CD40, anti-CD44, anti-CD52, anti-HER2 / neu (erbB2), anti-EGFR, anti-IGF, anti-VEGF, anti-TNFα, anti-IL2, anti-IL-36R and anti-IgE antibodies.

[0098] As used herein, the terms "antibody", "antibodies" or "immunoglobulin" relate to proteins selected from globulins that are naturally formed as a reaction of a host organism against foreign substances (=antigens) from differentiated B lymphocytes (plasma cells). There are various classes of immunoglobulins: IgA, IgD, IgE, IgG, IgM, IgY, IgW. Preferably, the antibody is an IgG antibody, more preferably an IgG1 or IgG4 antibody. The terms immunoglobulin and antibody are used interchangeably herein. Antibodies include monoclonal antibodies, monospecific antibodies and multispecific antibodies (e.g. bispecific antibodies or trispecific antibodies), single-chain antibodies, antigen-binding fragments of antibodies (e.g. Fab or F(ab')2 fragments), disulfide-linked Fvs, etc. Antibodies can be of any species and include chimeric antibodies and humanized antibodies. "Chimeric" antibodies are molecules in which antibody domains or regions are derived from different species. For example, the variable regions of the heavy and light chains can be derived from rat or mouse antibodies, and the constant regions can be derived from human antibodies. In "humanized" antibodies, only minimal sequences are derived from non-human species. Typically, only the CDR amino acid residues of human antibodies are replaced by CDR amino acid residues of non-human species such as mice, rats, rabbits or llamas. Sometimes, a few key framework amino acid residues that have an impact on antigen binding specificity and affinity are also replaced by non-human amino acid residues. Antibodies can be produced by chemical synthesis, by recombinant or transgenic means, by cell (e.g., hybridoma) culture or by other means.

[0099] Generally, an antibody is a tetrameric polypeptide consisting of two pairs of heterodimers, each of which is formed by a heavy chain and a light chain. Stabilization of both heterodimers and tetrameric polypeptide structures occurs via interchain disulfide bridges. Each chain consists of a domain called an "immunoglobulin domain" or "immunoglobulin region", whereby the terms "domain" or "region" are used interchangeably. Each domain contains about 70-110 amino acids and forms a compact three-dimensional structure. Both the heavy chain and the light chain contain a "variable domain" or "variable region" with less conserved sequences at their N-terminal ends, which is responsible for antigen recognition and binding. The variable region of the light chain is also referred to as "VL", while the variable region of the heavy chain is referred to as "VH".

[0100] Antigen binding fragments include, but are not limited to, for example, "Fab fragments" (Fragment of Antigen Binding = Fab). Fab fragments consist of the variable regions of two chains linked together by adjacent constant regions. These fragments can be formed from conventional antibodies by protease digestion, for example with papain, but similarly, Fab fragments can also be produced by genetic engineering. Further antibody fragments include F(ab')2 fragments, which can be prepared by proteolytic cleavage with pepsin.

[0101] Genetic engineering methods can be used to produce shortened antibody fragments consisting only of the variable regions of heavy chain (VH) and light chain (VL). These are referred to as Fv fragments (variable fragments = fragments of variable parts). Since these Fv fragments lack the covalent bonding of the two chains by the cysteine ​​of the constant chain, Fv fragments are often stable. It is advantageous to connect the variable regions of the heavy chain and light chain by short peptide fragments of, for example, 10 to 30 amino acids, preferably 15 amino acids. In this way, a single peptide chain consisting of VH and VL connected by a peptide linker is obtained. This antibody protein is called single-chain Fv (scFv). Examples of scFv-antibody proteins are known to those skilled in the art. Therefore, antibody fragments and antigen-binding fragments further include Fv fragments and particularly scFv.

[0102] In recent years, various strategies have been developed for the preparation of scFv as a multimer derivative. This is expected to result in recombinant antibodies with improved pharmacokinetic and biodistribution properties and increased binding affinity. In order to achieve the multimerization of scFv, scFv is prepared as a fusion protein with a multimerization domain. The multimerization domain can be, for example, the CH3 region of IgG or a coiled coil structure (helical structure), such as a leucine zipper domain. However, there are also strategies (such as double antibodies, three antibodies and five antibodies) in which the interaction between the VH / VL regions of scFv is used for multimerization. The double antibody referred to by the technician means a divalent homodimer scFv derivative. The shortening of the linker in the scFv molecule to 5-10 amino acids causes the formation of homodimers in which interchain VH / VL superposition occurs. Double antibodies can be stabilized by incorporating disulfide bridges in addition. The example of double antibody-antibody protein is known according to the prior art.

[0103] By minibodies the skilled person means bivalent homodimeric scFv derivatives. It consists of a fusion protein containing the CH3 region of an immunoglobulin, preferably IgG, most preferably IgG1 as a dimerization region, which is connected to the scFv via a hinge region (e.g. also from IgG1) and a linker region. Examples of minibodies - antibody proteins are known from the prior art.

[0104] By triabodies, the skilled person means: trivalent homotrimeric scFv derivatives. ScFv derivatives in which VH-VL are directly fused without a linker sequence leading to the formation of trimers.

[0105] Technicians are also familiar with so-called mini antibodies, which have a divalent, trivalent or tetravalent structure and are derived from scFv. Multimerization is carried out by dimeric, trimeric or tetrameric coiled-coil structures. In a preferred embodiment of the present invention, the gene of interest encodes any desired polypeptide mentioned above, preferably a monoclonal antibody, a derivative thereof or a fragment thereof.

[0106] The immunoglobulin fragment consisting of the CH2 and CH3 domains of the antibody heavy chain is called "Fc fragment", "Fc region" or "Fc" due to its tendency to crystallize (Fc = fragment crystallizable). These can be formed from conventional antibodies by protease digestion, for example with papain or pepsin, but can also be produced by genetic engineering. The N-terminal part of the Fc fragment may differ depending on how many amino acids are still present in the hinge region.

[0107] An antibody comprising an antigen binding fragment and an Fc region may also be referred to as a full-length antibody. A full-length antibody may be a monospecific antibody or a multispecific antibody, such as a bispecific antibody or a trispecific antibody.

[0108] Preferred therapeutic antibodies according to the present invention are multispecific antibodies, particularly bispecific antibodies or trispecific antibodies. Bispecific antibodies generally combine antigen binding specificity about target cells (e.g., malignant B cells) and effector cells (e.g., T cells, NK cells, or macrophages) in one molecule. Exemplary bispecific antibodies (but not limited thereto) are bispecific antibodies, BiTE (bispecific T cell adapter) forms, and DART (dual affinity retargeting) forms. The bispecific form separates the homologous variable domains of the heavy chain and light chain of two antigen binding specificities on two separate polypeptide chains, wherein the two polypeptide chains are non-covalently bound. The DART form is based on the bispecific form, but it provides additional stability through a C-terminal disulfide bridge. Trispecific antibodies are monoclonal antibodies combining three antigen binding specificities. They can be constructed based on bispecific antibody technology, which reconfigures the antigen recognition domains of two different antibodies into a bispecific molecule. For example, trispecific antibodies targeting CD38 on cancer cells and CD3 and CD28 on T cells have been generated. Multispecific antibodies are particularly difficult to produce with high product quality.

[0109] Another preferred therapeutic protein is a fusion protein, such as an Fc fusion protein. Therefore, the present invention can be advantageously used to produce a fusion protein, such as an Fc fusion protein. In addition, the method for increasing the protein produced according to the present invention can be advantageously used to produce a fusion protein, such as an Fc fusion protein.

[0110] The effect part of fusion protein can be the complete sequence of natural or modified heterologous protein or any part of sequence.Immunoglobulin protein constant domain sequence can be derived from any immunoglobulin subtype such as IgG1, IgG2, IgG3, IgG4, IgA1 or IgA2 subtype, or classification such as IgA, IgE, IgD or IgM.Preferentially, they are derived from human immunoglobulin, more preferably derived from human IgG, and even more preferably derived from human IgG1 and IgG2.The limiting examples of Fc fusion protein are MCP1-Fc, ICAM-Fc, EPO-Fc and scFv fragments etc. coupled with the CH2 domain of the heavy chain immunoglobulin constant region comprising N-linked glycosylation site.By introducing the CH2 domain of the heavy chain immunoglobulin constant region comprising N-linked glycosylation site into another expression construct comprising, for example, other immunoglobulin domains, enzymatic activity protein part or effector domain, Fc fusion protein can be constructed by genetic engineering method. Thus, the Fc fusion protein according to the present invention also comprises a single chain Fv fragment linked to the CH2 domain of a heavy chain immunoglobulin constant region comprising, for example, an N-linked glycosylation site.

[0111] The recombinant protein of interest of the present invention is produced in eukaryotic cells in cell culture. Preferably, the eukaryotic cell used to produce the recombinant protein of interest is a yeast cell (e.g., Saccharomyces, Kluyveromyces) or a mammalian cell (e.g., hamster or human cell). The yeast cell can be, but is not limited to, Saccharomyces cerevisiae, Pichia pastoris, Kluyveromyces lactis or Kluyveromyces marxianus. The mammalian cell is preferably a CHO cell, HEK 293 cell or a derivative thereof. HEK293 cells include, but are not limited to, HEK293 cells, HEK293T cells, HEK293F cells, Expi293F cells or derivatives thereof. Common CHO cells used for large-scale industrial production are often modified to improve their characteristics in the production process, or to promote the selection of recombinant cells. Such modifications include, but are not limited to, increasing resistance to apoptosis, decreasing autophagy, increasing cell proliferation, altering the expression of cell cycle regulatory proteins, molecular chaperone modification, modification of the unfolded protein response (UPR), modification of the secretory pathway, and metabolic modification.

[0112] Preferably, CHO cells allowing an efficient cell line development process are metabolically engineered, for example by glutamine synthetase (GS) knockout and / or dihydrofolate reductase (DHFR) knockout, to facilitate selection with methionine sulfoximine (MSX) or methotrexate, respectively.

[0113] Preferably, the CHO cell used to produce the recombinant protein of interest is a CHO-DG44 cell, a CHO-K1 cell, a CHO-DXB11 cell, a CHO-S cell, a CHO glutamine synthetase (GS)-deficient cell, or a derivative of any of these cells.

[0114] Non-limiting examples of mammalian cells that can be used in the context of the present invention are also summarized in Table A. However, derivatives / progeny of these cells, other mammalian cells, including but not limited to human, mouse, rat, monkey and rodent cell lines, can also be used in the present invention, particularly for the production of biopharmaceutical proteins, such as recombinant proteins of interest.

[0115] Table A: Exemplary mammalian production cell lines

[0116]

[0117] 1 CAP (Amniotic Cell Production of CEVEC) cells are an immortalized cell line based on primary human amniotic cells. They are generated by transfecting these primary cells with a vector containing functional E1 and pIX of adenovirus 5. CAP cells allow the competitive and stable production of recombinant proteins with excellent biological activity and therapeutic efficacy due to authentic human post-translational modifications.

[0118] At the time of establishment, the cells are most preferably adapted and cultured completely under serum-free conditions and optionally in a medium that does not contain any proteins / peptides of animal origin. Commercially available culture media such as Ham's F12 (Sigma, Deisenhofen, Germany), RPMI-1640 (Sigma), Dulbecco's Modified Eagle's Medium (DMEM; Sigma), Minimum Essential Medium (MEM; Sigma), Iscove's Modified Dulbecco's Medium (IMDM; Sigma), CD-CHO (Invitrogen, Carlsbad, CA), serum-free CHO medium (Sigma), and protein-free CHO medium (Sigma) are exemplary of appropriate nutrient solutions. Any culture medium may be supplemented with various compounds, non-limiting examples of which are recombinant hormones and / or other recombinant growth factors (e.g., insulin, transferrin, epidermal growth factor, insulin-like growth factor), salts (e.g., sodium chloride, calcium, magnesium, phosphate), buffers (e.g., HEPES), nucleosides (e.g., adenosine, thymidine), glutamine, glucose or other equivalent energy sources, antibiotics, and trace elements, as needed. Any other necessary supplements may also be included at appropriate concentrations known to those skilled in the art.For growth and selection of genetically modified cells expressing a selectable gene, a suitable selective agent is added to the culture medium.

[0119] The recombinant protein of interest of the method of the present invention is produced in the eukaryotic cell in cell culture. After expression, the recombinant protein is harvested and further purified. The recombinant protein of interest can be recovered from the culture medium as the secretory protein in the cell culture fluid (HCCF) of the harvest, or recovered from the cell lysate (that is, the fluid containing the content of the cell cracked by any means, the means including but not limited to the enzymatic, chemical, osmotic, mechanical and / or physical destruction of the cell membrane and optional cell wall), and purified using technology well known in the art. The sample obtained and / or analyzed during each step of purification is also referred to as process control (IPC) sample or process intermediate. Harvesting generally includes centrifugation and / or filtration, for example, to produce the cell culture fluid or cell lysate of harvest, preferably the cell culture fluid of harvest. Therefore, the cell culture fluid or cell lysate of harvest can also be referred to as the cell culture fluid of the harvest or the cell lysate of clarification. It does not contain living cells and cell debris, and most of the cell components have been removed. Clarification generally means centrifugation or filtration, preferably filtration. Further processing steps may include affinity chromatography, particularly for antibodies or protein A column chromatography containing Fc proteins, to separate the product from pollutants. Further processing steps may include acid treatment to inactivate viruses, clarifying the product pool by deep filtration, preferably after acid treatment, to remove cell pollutants, such as HCP and DNA. Further processing steps may include in this order or in any other order that may be appropriate in individual cases: ion exchange chromatography, particularly anion exchange chromatography to further remove contaminating cell components and / or cation exchange chromatography to remove product-related pollutants, such as aggregates. Further, preferably the following processing steps may include nanofiltration to further remove viruses and ultrafiltration and diafiltration to concentrate the recombinant protein of interest and exchange buffer respectively.

[0120] Since carboxylesterase and lipase activities are associated with host cell protein contaminants, the method according to the invention may be particularly useful for analyzing process intermediates after (preferably before and after) purification steps to remove HCPs, so as to adjust the relevant steps to more effectively remove carboxylesterase activity and / or lipase activity in process intermediates, such as before and after affinity chromatography, before and after depth filtration combined with acid treatment, and / or before and after anion exchange chromatography. In some embodiments, the method comprises obtaining at least one sample after affinity chromatography, and / or after depth filtration combined with acid treatment (or after acid treatment and / or after depth filtration), and / or after ion exchange chromatography, such as anion exchange chromatography and / or cation exchange chromatography, preferably anion exchange chromatography. In some embodiments, the method includes obtaining at least one sample before and after affinity chromatography, and / or before and after deep filtration combined with acid treatment (or before and after acid treatment and / or before and after deep filtration), and / or before and after ion exchange chromatography, such as anion exchange chromatography and / or cation exchange chromatography, preferably before and after anion exchange chromatography. It will be appreciated by those skilled in the art that the sample obtained after a certain method step may be the same as the sample obtained before the next method step, for example, the sample obtained after affinity chromatography (e.g., protein A chromatography) may be the same as the sample before acid treatment (or before deep filtration combined with acid treatment, i.e., after acid treatment). As explained above, due to the wide buffering range of the buffer, even the lipase activity in samples with different pH values ​​can be compared using the method according to the present invention. Other samples that can be analyzed using the method according to the present invention are samples (UF / DF samples) after ultrafiltration / diafiltration of bulk drug or drug product samples. Bulk drug or drug product samples contain formulation buffers and therefore often contain polysorbates. Under very high concentration, due to competition with substrate, polysorbate can suppress the hydrolysis reaction of lipophilic substrate 4-MU ester.However, due to the sensitivity of lipophilic substrate 4-MU ester determination, under the usual concentration of 0.4 to 0.8mg / ml polysorbate, lipase activity can also be determined in the final reaction mixture as explained above in the bulk drug or drug product sample of dilution.Hydrophilic substrate HPTS ester determination is slightly more sensitive to the polysorbate in the reaction, and polysorbate should not exceed 50 μ g / ml.Polysorbate is usually added to form bulk drug after ultrafiltration / diafiltration (after capture and refining step).Therefore, alternatively, UF / DF sample can be used for detecting carboxylesterase activity and / or lipase activity in (final) purified product.

[0121] The method for making the recombinant protein of interest generally comprises an ultrafiltration diafiltration step using tangential flow filtration (TTF) to provide a purified antibody product pool. The purified recombinant protein of interest is buffer exchanged and further concentrated by ultrafiltration. Polysorbate is then added to the concentrated antibody containing all other excipients of the formulation.

[0122] In one aspect, a method for making a recombinant protein of interest is provided, comprising the steps of: (i) culturing eukaryotic cells expressing the recombinant protein of interest in cell culture; (ii) harvesting the recombinant protein of interest; (iii) purifying the recombinant protein of interest; (iv) optionally formulating the recombinant protein of interest into a pharmaceutically acceptable formulation suitable for administration; and (v) obtaining at least one sample comprising the recombinant protein of interest in steps (ii), (iii) and / or (iv); wherein the method further comprises detecting carboxylesterase activity in the sample obtained in step (v) (i.e., the sample comprising the recombinant protein of interest and at least one contaminating host cell protein), comprising: (a) providing at least one sample obtained in step (v), the sample comprising the recombinant protein of interest produced in eukaryotic cells in cell culture and at least one contaminating host cell protein; (b) contacting the at least one sample with a reaction solution comprising a hydrophilic substrate to form a reaction mixture, wherein the reaction solution comprises: (i) a pH of about pH 4 to about pH 5; 8 buffer, (ii) a hydrophilic substrate, wherein the substrate is a saturated unbranched fatty acid (C6-C12) ester of 1-hydroxypyrene-3,6,8-trisulfonic acid or a salt thereof (substrate HPTS ester), and (iv) optionally a non-buffering salt; (c) incubating the sample and the substrate in the reaction mixture; and (d) detecting the carboxylesterase activity of at least one contaminating host cell protein by measuring the hydrolysis of the substrate HPTS ester and detecting the fluorescence intensity of the released chromophore HPTS; wherein the method optionally further comprises: (bi) contacting at least one sample of step (a) in a separate reaction setup comprising the recombinant protein of interest produced in eukaryotic cells in cell culture and at least one contaminating host cell protein with a reaction solution comprising the hydrophilic substrate to form a reaction mixture, wherein the reaction solution comprises: (i) a pH of about pH 4 to about pH 5 8, (ii) a lipophilic substrate comprising the chromophore 4-methylumbelliferone (4-MU) in the form of a 4-MU ester, wherein the 4-MU ester is a saturated unbranched fatty acid (C6-C16) 4-MU ester (substrate 4-MU ester), (iii) optionally a non-buffering salt, and (iv) a non-denaturing detergent without an ester bond, wherein the detergent is a non-ionic or zwitterionic detergent, (ci) incubating the sample and the substrate in the reaction mixture; (di) detecting the lipase activity of at least one contaminating host cell protein by measuring the hydrolysis of the 4-MU ester and detecting the fluorescence intensity of the released chromophore 4-MU; optionally, while incubating the sample and the substrate in the reaction mixture according to step (c) or (ci), measuring the hydrolysis by detecting the fluorescence intensity of the released chromophore HPTS or 4-MU over a period of time.Thus, in certain embodiments, the method further comprises detecting lipase activity in the sample (obtained in step (v)), comprising: (bi) contacting at least one sample of step (a) comprising the recombinant protein of interest produced in eukaryotic cells in cell culture and at least one contaminating host cell protein in a separate reaction setup with a reaction solution comprising a hydrophilic substrate to form a reaction mixture, wherein the reaction solution comprises: (i) a pH of about pH 4 to about pH 5; 8, (ii) a lipophilic substrate comprising the chromophore 4-methylumbelliferone (4-MU) in the form of a 4-MU ester, wherein the 4-MU ester is a saturated unbranched fatty acid (C6-C16) 4-MU ester (substrate 4-MU ester), (iii) optionally a non-buffering salt, and (iv) a non-denaturing detergent without an ester bond, wherein the detergent is a non-ionic or zwitterionic detergent, (ci) incubating the sample and the substrate in the reaction mixture; (di) detecting the lipase activity of at least one contaminating host cell protein by measuring the hydrolysis of the 4-MU ester and detecting the fluorescence intensity of the released chromophore 4-MU; optionally measuring the hydrolysis by detecting the fluorescence intensity of the released chromophore HPTS or 4-MU over a period of time while incubating the sample and the substrate in the reaction mixture according to step (c) or (ci), respectively. In certain embodiments, the recombinant protein of interest is a therapeutic protein, such as an antibody, an antibody fragment, an antibody-derived molecule (e.g., scFv, a bispecific or multispecific antibody), or a fusion protein (e.g., an Fc fusion protein). One skilled in the art will appreciate that the following steps may include several sub-steps: (i) culturing eukaryotic cells; (ii) harvesting the recombinant protein of interest; (iii) purifying the recombinant protein of interest; and (iv) optionally formulating the recombinant protein of interest. For example, step (iii) purifying the recombinant protein of interest may include the sub-step of purifying the recombinant protein of interest using affinity chromatography, acid treatment, depth filtration, and / or ion exchange chromatography.

[0123] In certain embodiments, the method for producing a recombinant protein of interest according to the present invention comprises obtaining at least one sample comprising the recombinant protein of interest in the step of harvesting the recombinant protein of interest (in step (ii)), wherein the sample is a harvested cell culture fluid (HCCF) or a cell lysate; in the step of purifying the recombinant protein of interest (in step (iii)), wherein the sample is an in-process control (IPC) sample; and / or in the optional step of formulating the recombinant protein of interest into a pharmaceutically acceptable formulation suitable for administration (in step (iv)), wherein the sample is a drug substance sample or a drug product sample. Preferably, the method for producing a recombinant protein of interest according to the present invention comprises obtaining at least one sample comprising the recombinant protein of interest in step (iii), wherein the sample is an in-process control (IPC) sample, for example comprising obtaining at least one sample after affinity chromatography, after depth filtration after acid treatment (or after acid treatment and / or after acid treatment), and / or after ion exchange chromatography, preferably anion exchange chromatography or cation exchange chromatography. More preferably, the method comprises obtaining at least one sample before and after affinity chromatography, before and after depth filtration after acid treatment (or before and after acid treatment and / or before and after acid treatment), and / or before and after ion exchange chromatography, preferably anion exchange chromatography or cation exchange chromatography. Other samples that can be analyzed using the method according to the invention are samples after ultrafiltration / diafiltration (UF / DF samples), bulk drug or drug product samples. Thus, in certain embodiments, the method comprises obtaining at least one sample comprising the recombinant protein of interest in step (ii), wherein the sample is a harvested cell culture fluid (HCCF) or a cell lysate; and / or in step (iii), wherein the sample is an in-process control (IPC) sample; and / or in step (iv), wherein the sample is a UF / DF sample, a drug substance sample or a drug product sample; preferably comprising obtaining at least one sample comprising the recombinant protein of interest and at least one contaminating host cell protein produced in eukaryotic cells in cell culture in step (iii), comprising obtaining at least one sample before and after affinity chromatography, before and after acid treatment, before and after depth filtration, and / or before and after ion exchange chromatography, preferably anion exchange chromatography or cation exchange chromatography. The step of detecting carboxylesterase or lipase activity in the sample comprising the recombinant protein of interest is performed according to and as specified in the method for detecting lipase activity as described herein.

[0124] In yet another aspect, the present invention relates to the use of a hydrophilic substrate HPTS ester and / or a lipophilic substrate 4-MU ester as a substrate for detecting carboxylesterase activity and / or lipase activity of at least one contaminating host cell protein in a sample in an assay, the sample comprising a recombinant protein of interest produced in eukaryotic cells in cell culture, wherein the hydrophilic substrate is a saturated unbranched fatty acid (C6-C12) ester of 1-hydroxypyrene-3,6,8-trisulfonic acid or a salt thereof (substrate HPTS ester), and wherein the lipophilic substrate is a saturated unbranched fatty acid (C6-C16) 4-MU ester. Preferably, the recombinant protein is produced in CHO cells and the at least one contaminating host cell protein is a CHO host cell protein (CHOP). In one embodiment, the use is the use of a hydrophilic substrate HPTS ester as a substrate for detecting carboxylesterase activity of at least one contaminating host cell protein in an assay, the sample comprising a recombinant protein of interest produced in eukaryotic cells in cell culture, wherein the hydrophilic substrate is a saturated unbranched fatty acid (C6-C12) ester of 1-hydroxypyrene-3,6,8-trisulfonic acid or a salt thereof (substrate HPTS ester). In a preferred embodiment, the use is the use of a hydrophilic substrate HPTS ester and a lipophilic substrate 4-MU ester as substrates for detecting carboxylesterase and lipase activity of at least one contaminating host cell protein in an assay, the sample comprising a recombinant protein of interest produced in eukaryotic cells in cell culture, wherein the hydrophilic substrate is a saturated unbranched fatty acid (C6-C12) ester of 1-hydroxypyrene-3,6,8-trisulfonic acid or a salt thereof (substrate HPTS ester), and wherein the lipophilic substrate is a saturated unbranched fatty acid (C6-C16) 4-MU ester. With regard to the components of the reaction solution, the sample and the conditions, the same applies as specified above for the method of the present invention.

[0125] Kit for determining contaminating lipase activity by measuring hydrolysis in a sample

[0126] Also provided is a kit for determining contaminating carboxylesterase activity and / or lipase activity in a sample containing a recombinant protein of interest, the kit comprising: (i) a buffer having a pH of about pH 4 to about pH 8; and (ii) a hydrophilic substrate and a lipophilic substrate, wherein (a) the hydrophilic substrate is a saturated unbranched fatty acid (C6-C12) ester of 1-hydroxypyrene-3,6,8-trisulfonic acid or a salt thereof (substrate HPTS ester); and (b) the lipophilic substrate comprises the chromophore 4-methylumbelliferone (4-MU) in the form of a 4-MU ester, wherein the 4-MU ester is a saturated unbranched fatty acid (C6-C16) 4-MU ester (substrate 4-MU ester); and optionally (iii) a non-buffered salt; and / or (iv) a non-denaturing detergent having no ester bond, wherein the detergent is a nonionic or zwitterionic detergent. The kit may further optionally comprise water for dilution. The hydrophilic substrate and the lipophilic substrate are used in separate reaction settings. Only the reaction solution containing the lipophilic substrate is prepared, which contains a non-denaturing detergent. Therefore, a reaction solution containing the hydrophilic substrate is prepared, which does not contain a non-denaturing detergent and / or any detergent, in particular any detergent above its CMC. In certain embodiments, the kit further comprises a manual with the following instructions: preparing a reaction solution containing a lipophilic substrate, which contains a non-denaturing detergent, and preparing a reaction solution containing a hydrophilic substrate, which does not contain a non-denaturing detergent.

[0127] In one embodiment, the kit further includes an internal standard that serves as a positive control and / or allows calculation of a relative value compared to an internal standard, such as commercially available carboxylase and / or lipase, such as porcine pancreatic lipase (PPL) crude extract. The kit can also include one or more microtiter plates with 96 holes or multiples of 96 holes. Kit components can be provided as solutions and / or dry components, separately or in premixed form. Buffer can be provided as a dry compound, providing a buffer of pH about pH 4 to about pH 8 after dilution or reconstruction.

[0128] In certain embodiments, a buffer for a reaction solution containing a hydrophilic substrate and an optional non-buffering salt, or a buffer for a reaction solution containing a lipophilic substrate and an optional non-buffering salt and / or an optional detergent are premixed as an assay buffer. Preferably, the assay buffer is at least about 3 times concentrated or about 3 times to about 5 times concentrated relative to the final reaction mixture. Alternatively, the assay buffer is provided as a dry mixture. Such a dry mixture can be reconstituted with water to provide the assay buffer that is at least about 3 times concentrated or 5 times concentrated relative to the final reaction mixture. In one embodiment, the dry mixture of the assay buffer is a lyophilized assay buffer. The substrate is provided separately and added to the assay buffer before use to provide a reaction solution. Alternatively, the kit may include a buffer, a substrate and an optional non-buffering salt and / or an optional detergent premixed as a master mixture. The master mixture may be suitable for providing at about 80% (v / v) to about 70% (v / v) of the reaction mixture, preferably at about 80% to about 75% of the reaction mixture. The assay buffer and the reaction solution are aqueous solutions.

[0129] For the components of the reaction solution, the same applies as specified above for the method of the present invention. The hydrophilic substrate HPTS ester is a saturated unbranched fatty acid (C6-C12, preferably C8-C12) ester of 1-hydroxypyrene-3,6,8-trisulfonic acid or its salt (substrate HPTS ester). Therefore, the hydrophilic substrate HPTS ester can be 1-hexanoyloxy-pyrene-3,6,8-trisulfonic acid or its salt, 1-heptanoyloxy-pyrene-3,6,8-trisulfonic acid or its salt, 1-octanoyloxy-pyrene-3,6,8-trisulfonic acid or its salt (OPTS), 1-nonanoyloxy-pyrene-3,6,8-trisulfonic acid or its salt, 1-decanoyloxy-pyrene-3,6,8-trisulfonic acid or its salt, 1-undecanoyloxy-pyrene-3,6,8-trisulfonic acid or its salt and 1-dodecanoyloxy-pyrene-3,6,8-trisulfonic acid or its salt. In certain embodiments, the hydrophilic substrate HPTS ester is selected from 1-octanoyloxy-pyrene-3,6,8-trisulfonic acid or its salt (OPTS), 1-nonanoyloxy-pyrene-3,6,8-trisulfonic acid or its salt and 1-decanoyloxy-pyrene-3,6,8-trisulfonic acid or its salt. In certain preferred embodiments, the hydrophilic substrate HPTS ester is 1-octanoyloxy-pyrene-3,6,8-trisulfonic acid or its salt (OPTS), preferably 1-octanoyloxy-pyrene-3,6,8-trisulfonic acid trisodium salt.

[0130] The lipophilic substrate comprising the chromophore 4-MU is in the form of a saturated unbranched fatty acid (C6 to C16) 4-MU ester (substrate 4-MU ester), wherein the fatty chain of the saturated unbranched fatty acid has C6 to C16 carbon atoms or preferably C8 to C12 carbon atoms. Thus, the lipophilic substrate 4-MU ester can be 4-methylumbelliferyl octanoate, 4-methylumbelliferyl nonanoate, 4-methylumbelliferyl decanoate (4-MUD), methylumbelliferyl undecanoate or methylumbelliferyl dodecanoate. In certain embodiments, the lipophilic substrate is selected from 4-methylumbelliferyl octanoate, 4-methylumbelliferyl decanoate (4-MUD) and 4-methylumbelliferyl dodecanoate, and in a preferred embodiment, the lipophilic substrate is 4-MUD.

[0131] The kit may further comprise an organic solvent for dissolving the lipophilic substrate, or the lipophilic substrate is dissolved in an organic solvent. The lipophilic substrate may be provided as a dry substance and optionally an additional organic solvent, or may be dissolved in an organic solvent, such as dimethyl sulfoxide (DMSO) or dimethylformamide (DMF), preferably in DMSO as a stock solution (such as a stock solution of 100x relative to the concentration in the reaction mixture). The kit may further comprise water for dissolving the hydrophilic substrate. The lipophilic substrate may be provided as a dry substance, and should be frozen after dissolving in an aqueous solution such as water or an aqueous buffer.

[0132] Examples of suitable non-denaturing zwitterionic detergents without ester bonds (for reaction solutions containing lipophilic substrates) are, but are not limited to, 3-[(3-cholamidopropyl)dimethylammonium]-1-propanesulfonate (CHAPS), 3-([3-cholamidopropyl)dimethylammonium]-2-hydroxy-1-propanesulfonate (CHAPSO), CHAPS analogs (e.g., Big CHAP N,N-bis-(3-D-glucosamidopropyl)deoxycholamid), Zwittergent (different lengths, e.g., n-dodecyl-N,N-dimethyl-3-ammonium-1-propanesulfonate (Zwittergent 3-12)), and 3-[N,N-dimethyl(3-palmitamidopropyl)ammonium]-propanesulfonate or other aminosulfobetaine detergents. Examples of suitable non-denaturing nonionic detergents are, but are not limited to, pyranoside surfactants (e.g., octyl β-D-glucopyranoside (OGP), nonyl β-D-glucopyranoside, dodecyl β-D-maltopyranoside (DDM) or octyl β-D-thioglucopyranoside), polyoxyethylene (23) lauryl ether (Brij 35) or other polyoxyethylene ethers; saponins (e.g., digitonin), octylphenoxypolyethoxyethanol (IGEPAL CA-630), poloxamer 188, 338, 407 or tergitol. In certain embodiments, the detergent is a non-denaturing nonionic or zwitterionic detergent that does not have an ester bond, preferably the detergent is not polyethylene glycol tert-octylphenyl ether (Triton X-100) or polyethylene glycol nonylphenyl ether (NP-40). In a preferred embodiment, the detergent is a non-denaturing nonionic or zwitterionic detergent selected from CHAPS, CHAPSO, Zwittergent (e.g. Zwittergent 3-12) and saponin, preferably CHAPS. The detergent is only required in reaction solutions containing lipophilic substrates, while the detergent should be omitted from reaction solutions containing hydrophilic substrates.

[0133] In certain embodiments, the buffer comprises one or more buffer substances selected from the group consisting of formic acid, acetic acid, lactic acid, citric acid, malic acid, maleic acid, glycine, glycylglycine, succinic acid, TES (2-{[tris(hydroxymethyl)methyl]amino}ethanesulfonic acid), MOPS (3-(N-morpholino)propanesulfonic acid), PIPES (piperazine-N,N'-bis(2-ethanesulfonic acid)), MES (2-(N-morpholino)ethanesulfonic acid), Tris base, Tris, Bis-Tris, Bis-Tris-propane, Bicine (N,N-bis(2-hydroxyethyl)glycine), HEPES (4-2-hydroxyethyl-1-piperazineethanesulfonic acid), TAPS (3-([tris(hydroxymethyl)methyl]amino}propanesulfonic acid), Tricine (N-tris(hydroxymethyl)methylglycine), Na2HPO4, and NaH2PO4. In certain embodiments, the buffer has a pH of about pH 4 to about pH 8, preferably the buffer has a pH of about pH 4 to about pH 8. 5 to about pH 7.5, more preferably the buffer has a pH of about pH 5.5 to about pH 7.5.

[0134] The buffer may comprise a single buffer substance, or may be a multi-component buffer as specified above for the method according to the invention. The multi-component buffer may comprise more than one buffer substance with overlapping buffer ranges, so as to have a wider buffer range. The buffer may for example comprise two, three, four, five or more buffer substances, preferably two or more buffer substances, more preferably three or more buffer substances. For example, the multi-component buffer may comprise two to four buffer substances, three to four buffer substances, more preferably three buffer substances. In certain embodiments, the multi-component buffer comprises at least three buffer substances with overlapping buffer ranges, preferably comprises at least one of Tris, MES and / or acetic acid, more preferably acetic acid, MES and Tris in a ratio of 1:1:2. In certain embodiments, the buffer is a multi-component buffer having a buffer range of at least about pH 5 to at least about pH 7.5, preferably at least about pH 4 to at least about pH 8. In one embodiment, the use of a multi-component buffer at different pH values ​​between about pH 4 and about pH 8 affects the ionic strength of the buffer by less than 15%, preferably less than 10%, or even less than 7.5% or less than 5%, such as from 0% to less than 15%, from 0% to less than 10%, from 0% to less than 7.5%, or from 0% to less than 5%, or such as from 2% to less than 15%, from 2% to less than 10%, from 2% to less than 7.5%, or from 2% to less than 5%. The optional non-buffering salt can be, for example, NaCl, KCl, and CaCl2, and is preferably NaCl or KCl.

[0135] In view of the above, it should be understood that the present invention also covers the following items:

[0136] Item 1 provides a method for detecting carboxylesterase activity of a contaminating host cell protein in a sample containing a recombinant protein of interest produced in a eukaryotic cell, comprising (a) providing at least one sample containing a recombinant protein of interest produced in a eukaryotic cell in cell culture and at least one contaminating host cell protein; (b) contacting at least one sample with a reaction solution (containing a hydrophilic substrate) to form a reaction mixture, wherein the reaction solution comprises: (i) a pH of about pH 4 to about pH 5; 8, (ii) a hydrophilic substrate, wherein the substrate is a saturated unbranched fatty acid (C6-C12) ester of 1-hydroxypyrene-3,6,8-trisulfonic acid or a salt thereof (substrate HPTS ester), and (iii) optionally a non-buffering salt; (c) incubating the sample and the substrate in the reaction mixture; (d) detecting the carboxylesterase activity of at least one contaminating host cell protein by measuring the hydrolysis of the substrate HPTS ester and detecting the fluorescence intensity of the released chromophore 1-hydroxypyrene-3,6,8-trisulfonic acid or a salt thereof (HPTS); and optionally measuring the hydrolysis by detecting the fluorescence intensity of the released chromophore HPTS over a period of time while incubating the sample and the substrate in the reaction mixture according to step (c).

[0137] Item 2 specifies the method of item 1, wherein the sample and substrate in the reaction mixture are incubated for any time period between 2 minutes to 5 hours, 2 minutes to 3 hours, 2 minutes to 2 hours, or 2 minutes to 0.5 hours.

[0138] Item 3 specifies the method of item 1 or item 2, wherein the reaction mixture has a volume of 300 μl and / or multiple reaction mixtures (e.g., 12 or more, 24 or more, 36 or more, 72 or more, or 96 or more) are preferably analyzed in parallel with a volume of 300 μl or less.

[0139] Item 4 specifies the method of any of the preceding items, wherein a portion of at least one sample is used for each reaction mixture.

[0140] Item 5 specifies the method of any of the preceding items, wherein the fluorescence of the released chromophore HPTS is determined using an excitation wavelength in the range of 401-405 nm and an emission wavelength in the range of 510-516 nm.

[0141] Item 6 specifies the method of any one of the previous items, wherein the substrate HPTS ester is selected from 1-octanoyloxy-pyrene-3,6,8-trisulfonic acid or its salt (OPTS), 1-nonanoyloxy-pyrene-3,6,8-trisulfonic acid or its salt and 1-decanoyloxy-pyrene-3,6,8-trisulfonic acid or its salt, preferably selected from 1-octanoyloxy-pyrene-3,6,8-trisulfonic acid (OPTS) trisodium salt, 1-nonanoyloxy-pyrene-3,6,8-trisulfonic acid trisodium salt and 1-decanoyloxy-pyrene-3,6,8-trisulfonic acid trisodium salt.

[0142] Item 7 specifies the method of any of the preceding items, wherein the reaction solution (comprising the hydrophilic substrate) does not contain a detergent.

[0143] Item 8 specifies the method of any of the previous items, wherein the hydrophilic substrate HPTS ester is dissolved in an aqueous solution, preferably an aqueous solution without DMSO or DMF

[0144] Item 9 specifies the method of any one of the previous items, wherein the hydrophilic substrate HPTS ester is used in the reaction mixture at a final concentration of 50 μM or less, preferably 30 μM or less.

[0145] Item 10 specifies the method of any of the preceding items, wherein the method comprises: (bi) contacting at least one sample of step (a) comprising the recombinant protein of interest produced in eukaryotic cells in cell culture and at least one contaminating host cell protein in a separate reaction setup with a reaction solution comprising a lipophilic substrate to form a reaction mixture, wherein the reaction solution comprises: (i) a pH of about pH 4 to about pH 8, (ii) a lipophilic substrate comprising the chromophore 4-methylumbelliferone (4-MU) in the form of a 4-MU ester, wherein the 4-MU ester is a saturated unbranched fatty acid (C6-C16) 4-MU ester, (iii) optionally a non-buffering salt, and (iv) a non-denaturing detergent without an ester bond, wherein the detergent is a non-ionic or zwitterionic detergent; (ci) incubating the sample and substrate in the reaction mixture of step (bi); and (di) detecting the lipase activity of at least one contaminating host cell protein by measuring the hydrolysis of the substrate 4-MU ester and detecting the fluorescence intensity of the released chromophore 4-MU; optionally measuring the hydrolysis by detecting the fluorescence intensity of the released chromophore 4-MU over a period of time while incubating the sample and substrate in the reaction mixture according to step (ci).

[0146] Item 11 specifies the method of Item 10, wherein the substrate is selected from 4-methylumbelliferyl octanoate, 4-methylumbelliferyl nonanoate, 4-methylumbelliferyl decanoate (4-MUD), 4-methylumbelliferyl undecanoate and 4-methylumbelliferyl dodecanoate.

[0147] Item 12 specifies the method of item 10 or 11, wherein the substrate is provided in the reaction mixture at a final concentration of about 1 μM to about 1 mM.

[0148] Item 13 specifies the method of any one of items 10-12, wherein the substrate is provided as a stock solution in an organic solvent and wherein the stock solution is added at about 1% to about 5% (v / v) of the reaction mixture and / or wherein the organic solvent is DMSO or DMF.

[0149] Item 14 specifies the method of any one of items 10-13, wherein the detergent has a final concentration in the reaction mixture that is higher than its critical micelle concentration in the reaction mixture.

[0150] Item 15 specifies the method of any one of items 10-14, wherein the detergent is selected from CHAPS, CHAPSO and Zwittergent, preferably CHAPS, and / or is not polyethylene glycol tert-octylphenyl ether (Triton X-100) nor polyethylene glycol nonylphenyl ether (NP-40).

[0151] Item 16 specifies the method of any one of items 10-15, wherein the detergent is CHAPS and is provided in the reaction mixture at a final concentration of about 8 mM to about 20 mM, preferably about 8 mM to about 15 mM, more preferably about 10 mM.

[0152] Item 17 specifies the method of any of the previous items, wherein the fluorescence intensity of the released chromophore HPTS and optionally 4-MU is detected without stopping the hydrolysis of the hydrophilic substrate HPTS ester and optionally the lipophilic substrate 4-MU ester; and / or the sample and substrate in the reaction mixture are incubated for any time period between 2 minutes to less than 5 hours, less than 3 hours, less than 2 hours or less than 0.5 hours.

[0153] Item 18 specifies the method of any of the previous items, wherein the fluorescence intensity of the released chromophore HPTS and optionally 4-MU is detected over a period of time and a pseudo-zero-order reaction rate is followed, and optionally, wherein reaction mixtures that do not meet the pseudo-zero-order reaction rate requirement are excluded from the analysis.

[0154] Item 19 specifies the method of any of the previous items, further comprising the steps of: (a) determining the hydrolysis rate by detecting the fluorescence intensity of the released chromophore HPTS and optionally 4-MU as relative fluorescence units (RFU), and determining the amount (mol / s) of the released chromophore HPTS and optionally 4-MU by comparing it with a calibration curve generated using a defined concentration of 4MU, and / or (b) calculating a relative value compared to an internal standard.

[0155] Item 20 specifies the method of any one of the previous items, wherein the buffer comprises one or more buffer substances selected from the group consisting of formic acid, acetic acid, lactic acid, citric acid, malic acid, maleic acid, glycine, glycylglycine, succinic acid, TES (2-{[tris(hydroxymethyl)methyl]amino}ethanesulfonic acid), MOPS (3-(N-morpholino)propanesulfonic acid), PIPES (piperazine-N,N'-bis(2-ethanesulfonic acid)), MES (2-(N-morpholino)ethanesulfonic acid), Tris base, Tris, Bis-Tris, Bis-Tris-propane, Bicine (N,N-bis(2-hydroxyethyl)glycine), HEPES (4-2-hydroxyethyl-1-piperazineethanesulfonic acid), TAPS (3-([tris(hydroxymethyl)methyl]amino}propanesulfonic acid), Tricine (N-tris(hydroxymethyl)methylglycine), Na2HPO4 and NaH2PO4.

[0156] Item 21 specifies the method of any one of the previous items, wherein the buffer has a pH of about 5 to about 7.5, preferably the buffer has a pH of about 5.5 to about 7.5.

[0157] Item 22 specifies the method of any of the previous items, wherein the buffer is a multi-component buffer having a buffer range of at least about pH 5 to at least about pH 7.5, preferably at least about pH 4 to at least about pH 8.

[0158] Item 23 specifies the method of item 22, wherein the multi-component buffer comprises at least three buffer substances with overlapping buffer ranges, preferably comprising at least one of Tris, MES and / or acetic acid.

[0159] Item 24 specifies the method of item 22 or 23, wherein the method includes (a) using a buffer having a variable pH of at least about pH 4 to at least about pH 8; (b) using a buffer having different pH values ​​between about pH 4 and about pH 8, thereby affecting the ionic strength by less than 15%, preferably less than 10%, preferably from 0% to less than 15%, from 0% to less than 10%, from 0% to less than 7.5% or from 0% to less than 5%; (c) adjusting the pH of the buffer to the pH of the sample; (d) adjusting the pH of the buffer to a value close to the optimal value of at least one (contaminating) host cell protein having carboxylase and / or lipase activity; or (e) comparing and identifying conditions that reduce hydrolytic activity.

[0160] Item 25 specifies the method of any of the previous items, wherein at least 2, 3, 4, 5, 10 or more samples are analyzed simultaneously.

[0161] Item 26 specifies the method of any one of the previous items, wherein the non-buffering salt is selected from NaCl, KCl and CaCl2, preferably wherein the non-buffering salt is NaCl or KCl.

[0162] Item 27 specifies the method of any one of the previous items, wherein the non-buffering salt has a concentration in the reaction mixture of about 100 mM to about 200 mM, preferably about 130 mM to about 170 mM, more preferably about 140 mM to about 150 mM.

[0163] Item 28 specifies the method of any of the previous items, wherein the ionic strength of the non-buffer salt is about 200 mM or less in the reaction mixture, preferably about 150 mM or less in the reaction mixture, preferably about 100 mM to about 200 mM in the reaction mixture, preferably about 130 mM to about 170 mM, and more preferably about 140 mM to about 150 mM.

[0164] Item 29 specifies the method of any one of the previous items, wherein the cumulative ionic strength of the buffer and non-buffer salt in the reaction mixture is about 450 mM or less, preferably about 400 mM, more preferably 350 mM or less in the reaction mixture.

[0165] Item 30 specifies the method of any of the preceding items, wherein fluorescence is detected using a fluorescence spectrometer or a microplate spectrophotometer.

[0166] Item 31 specifies the method of item 30, wherein fluorescence is detected using a microplate spectrophotometer in a bottom reading mode or a top reading mode, preferably in a bottom reading mode.

[0167] Item 32 specifies the method of any of the preceding items, wherein the sample is contacted, incubated and measured in one or more microtiter plates having 96 wells or multiples of 96 wells.

[0168] Item 33 specifies the method of any of the preceding items, wherein a portion of at least one sample is used for each reaction mixture.

[0169] Item 34 specifies a method as in any of the previous items, wherein the at least one sample (or a portion of at least one sample) is provided at about 20% to about 30% (v / v) of the reaction mixture, preferably at about 25% of the reaction mixture, optionally wherein the sample (or a portion of at least one sample) is pre-diluted.

[0170] Item 35 specifies the method of any of the previous items, wherein at least one of the samples is a harvested cell culture fluid (HCCF) or cell lysate, an in-process control (IPC) sample, a UF / DF sample, a drug substance sample, or a drug product sample.

[0171] Item 36 specifies the method of any of the previous items, wherein (a) the recombinant protein of interest is not a carboxylesterase or lipase and / or an enzyme having carboxylesterase or lipase activity; and / or (b) the recombinant protein of interest is selected from antibodies, antibody fragments, antibody-derived molecules and fusion proteins.

[0172] Item 37 specifies the method of any one of the previous items, wherein the eukaryotic cell used to produce the recombinant protein of interest is a yeast cell or a mammalian cell, wherein the mammalian cell is preferably a CHO cell, a HEK 293 cell or a derivative thereof.

[0173] Item 38 specifies the method of any of the previous items, wherein the recombinant protein of interest is produced in CHO cells and the at least one contaminating host cell protein is a CHO host cell protein (CHOP).

[0174] Item 39 provides a method for making a recombinant protein of interest, comprising the following steps: (i) culturing eukaryotic cells expressing the recombinant protein of interest in cell culture; (ii) harvesting the recombinant protein of interest; (iii) purifying the recombinant protein of interest; and (iv) optionally formulating the recombinant protein of interest into a pharmaceutically acceptable formulation suitable for administration; and (v) obtaining at least one sample containing the recombinant protein of interest in steps (ii), (iii) and / or (iv); wherein the method further comprises detecting carboxylesterase activity in the sample containing the recombinant protein of interest and at least one contaminating host cell protein, comprising: (a) providing at least one sample obtained in step (v), wherein the sample contains the recombinant protein of interest produced in eukaryotic cells in cell culture and at least one contaminating host cell protein; (b) contacting at least one sample with a reaction solution containing a hydrophilic substrate to form a reaction mixture, wherein the reaction solution contains: (i) a pH of about pH 4 to about pH 5; 8 buffer, (ii) a hydrophilic substrate, wherein the substrate is a saturated unbranched fatty acid (C6-C12) ester of 1-hydroxypyrene-3,6,8-trisulfonic acid or a salt thereof (substrate HPTS ester), and (iv) optionally a non-buffering salt; (c) incubating the sample and the substrate in the reaction mixture; and (d) detecting the carboxylesterase activity of at least one contaminating host cell protein by measuring the hydrolysis of the substrate HPTS ester and detecting the fluorescence intensity of the released chromophore HPTS; wherein the method optionally further comprises detecting the lipase activity in the sample, which comprises (bi) contacting at least one sample of step (a) in a separate reaction setup comprising the recombinant protein of interest produced in eukaryotic cells in cell culture and at least one contaminating host cell protein with a reaction solution comprising the lipophilic substrate to form a reaction mixture, wherein the reaction solution comprises: (i) a pH of about pH 4 to about pH 5 8, (ii) a lipophilic substrate comprising the chromophore 4-methylumbelliferone (4-MU) in the form of a 4-MU ester, wherein the 4-MU ester is a saturated unbranched fatty acid (C6-C16) 4-MU ester, (iii) optionally a non-buffering salt, and (iv) a non-denaturing detergent without an ester bond, wherein the detergent is a non-ionic or zwitterionic detergent, (ci) incubating the sample and the substrate in the reaction mixture; (di) detecting the lipase activity of at least one contaminating host cell protein by measuring the hydrolysis of the substrate 4-MU ester and detecting the fluorescence intensity of the released chromophore 4-MU; optionally, while incubating the sample and the substrate in the reaction mixture according to step (c) or (ci), measuring the hydrolysis by detecting the fluorescence intensity of the released chromophore HPTS or 4-MU over a period of time.

[0175] Item 40 specifies a method for manufacturing a recombinant protein of interest according to Item 39, wherein the method comprises obtaining at least one sample containing the recombinant protein of interest in step (ii), wherein the sample is a harvested cell culture fluid (HCCF) or a cell lysate; in step (iii), wherein the sample is an in-process control (IPC) sample; and / or in step (iv), wherein the sample is a UF / DF sample, a drug substance sample, or a drug product sample.

[0176] Item 41 specifies a method for producing a recombinant protein of interest according to item 39 or 40, comprising obtaining at least one sample containing the recombinant protein of interest in step (iii), wherein the sample is an in-process control (IPC) sample.

[0177] Item 42 specifies a method for producing a recombinant protein of interest according to Item 41, wherein the method comprises obtaining at least one sample after affinity chromatography, after depth filtration after acid treatment (or after acid treatment and / or after depth filtration), and / or after anion exchange chromatography, preferably obtaining at least one sample before and after affinity chromatography, before and after depth filtration after acid treatment (or before and after acid treatment and / or before and after depth filtration), and / or before and after anion exchange chromatography.

[0178] Item 43 specifies a method for producing a recombinant protein of interest according to any one of items 39-42, which comprises detecting carboxylesterase and optionally lipase activity in a sample containing the recombinant protein of interest produced in eukaryotic cells in cell culture and at least one contaminating host cell protein according to the method of any one of items 1-38.

[0179] Item 44 provides a kit for determining contaminating carboxylesterase activity and / or lipase activity in a sample containing a recombinant protein of interest, the kit comprising: (i) a buffer having a pH of about pH 4 to about pH 8; and (ii) a hydrophilic substrate and a lipophilic substrate, wherein (a) the hydrophilic substrate is a saturated unbranched fatty acid (C6-C12) ester of 1-hydroxypyrene-3,6,8-trisulfonic acid or a salt thereof (substrate HPTS ester); and (b) the lipophilic substrate comprises the chromophore 4-methylumbelliferone (4-MU) in the form of a 4-MU ester, wherein the 4-MU ester is a saturated unbranched fatty acid (C6-C16) 4-MU ester (substrate 4-MU ester); and optionally (iii) a non-buffering salt; and / or (iv) a non-denaturing detergent having no ester bond, wherein the detergent is a nonionic or zwitterionic detergent.

[0180] Item 45 further specifies a kit according to Item 44, wherein the hydrophilic substrate HPTS ester is selected from 1-octanoyloxy-pyrene-3,6,8-trisulfonic acid or its salt (OPTS), 1-nonanoyloxy-pyrene-3,6,8-trisulfonic acid or its salt and 1-decanoyloxy-pyrene-3,6,8-trisulfonic acid or its salt, preferably selected from 1-octanoyloxy-pyrene-3,6,8-trisulfonic acid (OPTS) trisodium salt, 1-nonanoyloxy-pyrene-3,6,8-trisulfonic acid trisodium salt and 1-decanoyloxy-pyrene-3,6,8-trisulfonic acid trisodium salt.

[0181] Item 46 further specifies a kit according to item 44 or 45, wherein the lipophilic substrate 4-MU ester is selected from 4-methylumbelliferyl octanoate, 4-methylumbelliferyl nonanoate, 4-methylumbelliferyl decanoate (4-MUD), 4-methylumbelliferyl undecanoate and 4-methylumbelliferyl dodecanoate.

[0182] Item 47 further specifies a kit according to any one of items 44-46, wherein the kit further comprises one or more microtiter plates having 96 wells or a multiple of 96 wells.

[0183] Item 48 specifies the kit of any one of items 44-47, further comprising an organic solvent for dissolving the lipophilic substrate 4-MU ester, preferably DMSO or DMF.

[0184] Item 49 specifies a kit of any one of items 44-48, wherein the detergent is neither polyethylene glycol tert-octylphenyl ether (Triton X-100) nor polyethylene glycol nonylphenyl ether (NP-40), or wherein the detergent is a non-denaturing zwitterionic detergent selected from CHAPS, CHAPSO and Zwittergent, preferably CHAPS.

[0185] Item 50 specifies a kit of any one of items 44-49, wherein the buffer comprises one or more buffer substances selected from the group consisting of formic acid, acetic acid, lactic acid, citric acid, malic acid, maleic acid, glycine, glycylglycine, succinic acid, TES (2-{[tris(hydroxymethyl)methyl]amino}ethanesulfonic acid), MOPS (3-(N-morpholino)propanesulfonic acid), PIPES (piperazine-N,N'-bis(2-ethanesulfonic acid)), MES (2-(N-morpholino)ethanesulfonic acid), Tris base, Tris, Bis-Tris, Bis-Tris-propane, Bicine (N,N-bis(2-hydroxyethyl)glycine), HEPES (4-2-hydroxyethyl-1-piperazineethanesulfonic acid), TAPS (3-([tris(hydroxymethyl)methyl]amino}propanesulfonic acid), Tricine (N-tris(hydroxymethyl)methylglycine), Na2HPO4 and NaH2PO4.

[0186] Item 51 specifies the kit of any one of items 44-50, wherein the buffer has a pH of about 5 to about 7.5, preferably the buffer has a pH of about 5.5 to about 7.5.

[0187] Item 52 specifies the kit of any one of items 44-51, wherein the buffer is a multi-component buffer having a buffer range of at least about pH 5 to at least about pH 7.5, preferably at least about pH 4 to at least about pH 8.

[0188] Item 53 specifies the kit of item 52, wherein the multi-component buffer comprises at least three buffer substances with overlapping buffer ranges, preferably comprising at least one of Tris, MES and / or acetic acid.

[0189] Item 54 specifies the kit of any one of items 44 to 53, wherein the non-buffering salt is selected from NaCl, KCl and CaCl2, preferably wherein the non-buffering salt is NaCl or KCl.

[0190] Item 55 provides the use of a hydrophilic substrate HPTS ester and a lipophilic substrate 4-MU ester as substrates for detecting carboxylesterase and lipase activities of at least one contaminating host cell protein in a sample in an assay, wherein the sample contains a recombinant protein of interest produced in eukaryotic cells in cell culture, preferably wherein the recombinant protein of interest is produced in CHO cells and the at least one contaminating host cell protein is a CHO host cell protein (CHOP), wherein the hydrophilic substrate is a saturated unbranched fatty acid (C6-C12) ester of 1-hydroxypyrene-3,6,8-trisulfonic acid or a salt thereof (substrate HPTS ester), and wherein the lipophilic substrate is a saturated unbranched fatty acid (C6-C16) 4-MU ester.

[0191] Item 56 specifies the use of a hydrophilic substrate HPTS ester as a substrate for detecting carboxylesterase activity of at least one contaminating host cell protein in a sample in an assay, the sample comprising a recombinant protein of interest produced in eukaryotic cells in cell culture, wherein the hydrophilic substrate is a saturated unbranched fatty acid (C6-C12) ester of 1-hydroxypyrene-3,6,8-trisulfonic acid or a salt thereof (substrate HPTS ester), and preferably wherein the recombinant protein is produced in CHO cells and the at least one contaminating host cell protein is a CHO host cell protein (CHOP).

[0192] Item 57 specifies the use of item 55 or 56, which comprises detecting carboxylesterase and optionally lipase activity in a sample containing a recombinant protein of interest produced in eukaryotic cells in cell culture and at least one contaminating host cell protein according to the method of any one of items 1-38.

[0193] Example

[0194] A new assay was developed to characterize the activity of esterases (e.g., carboxylesterases) that preferentially convert hydrophilic substrates. This assay is used to investigate various biotechnological or biopharmaceutical related solutions that may potentially contain trace amounts of enzyme impurities, such as lipases and other esterases, in addition to various stabilizing substances (buffer substances, additives for adjusting the ionic strength, and detergents). The following method was used in the examples.

[0195] Fluorescence spectroscopy measurement

[0196] In order to be able to determine the enzymatic activity, the substrate 1-octanoyloxy-pyrene-3,6,8-trisulfonic acid trisodium salt (OPTS) was selected. Its hydrolysis product 1-hydroxypyrene-3,6,8-trisulfonic acid trisodium salt (HPTS) can be detected by fluorescence spectroscopy. The change in the fluorescence signal over a period of time is directly related to the change in the concentration of the free fluorophore. By setting up a linear fit with subsequent (R 2 ≥0.99) can be converted. Kinetic measurement experiments using OPTS / 4-MUD substrate assays were performed in duplicate. The reaction mixture without the protein of interest was deducted from the protein-containing batch, which served as the corresponding control. The buffer used for OPTS measurement (hydrophilic substrate) contained 0.3M HOAc, 0.3M MES, 0.6M TRIS and 0.6M NaCl (4x AMT buffer; acetate, MES, TRIS). For 4-MUD substrate measurement (lipophilic substrate), 0.04M CHAPS was additionally added. The buffer (AMT) was prepared at four times the concentration (4xAMT) and added to the reaction mixture at 25% (v / v). All measurements were performed in multiwell plates with a preparation volume of 300 μL (75 μL 4xAMT buffer, 30 μL substrate, 75 μL enzyme solution, x μL additives, 300 μL aqueous H2O). Unless otherwise stated, all fluorescence spectra were performed using 96-well, clear-bottom, non-binding plates (Greiner, Austria) on a SpectraMax M3 PlateReader (Molecular Device, USA) and recorded using SoftMax Pro 7.0.3 software (Molecular Device, USA). OPTS assay measurements were typically performed at 25°C, λ ex=403nm and λ em =512 nm, and the 4-MUD assay was performed at 25°C, λ ex =330nm and λ em =450nm. For evaluation, the fluorescence signal detected for the reaction mixture without the protein of interest (control) is deducted from the reaction mixture with the protein of interest (e.g. DS). Depending on the fluorescence intensity, the hydrolysis of the substrate is measured by real-time detection of the fluorescence intensity of the released chromophore (4-MU or HPTS) immediately after mixing for a few minutes up to 5 hours. The previously established linear fit (R 2 ≥0.99) to convert the fluorescence signal changes over a period of time into hydrolysis activity.

[0197] Create a calibration curve with a linear fit

[0198] In order to establish a calibration curve with a linear fit, a series of 1:1 dilutions of the free fluorophore HPTS from 12 μM to 7.8 nM were prepared in H2O. Each dilution of the HPTS solution was pipetted into the plate before adding the AMT buffer (composition: 75 μL 4xAMT (variable pH), 75 μL HPTS solution, 150 μL H2O). Calibration curves were generated for the different pH values ​​of the AMT buffer used (pH 4-8, in 0.5 steps). The final concentration range of HPTS used for the calibration curve was 3 μM to 1.46 nM. After pipetting, the measurement was started directly.

[0199] Kinetic measurements using OPTS / 4-MUD substrate and antibody preparations

[0200] The target concentration of OPTS is 25 μM, and the target concentration of 4-MUD is 30 μM. To prepare the master mix, 4x AMT buffer is mixed with an appropriate volume of H2O in a Falcon tube. Dialyzed antibody (Ab) preparation samples (drug substance) or control solutions (75 μl) are transferred to a 96-well plate. Optional inhibitors (10 μM orlistat, 1 mM PMSF and 10 mM EDTA) are added to a master mix containing 4x AMT buffer and water and substrate (3 μl / sample 3mM 4-MUD in DMSO or 30 μM / sample 250 μM OPTS in H2O, aliquoted and frozen). 4-MUD substrate is stored in DMSO as a concentrated stock solution containing 3 mM 4-methylumbelliferyl decanoate (4-MUD; FM25973, Carbosynth), resulting in a 100x stock solution containing 0.3 mM in DMSO for use. Prepare 250 μM OPTS stock solution in H2O, aliquot and freeze until use. Although OPTS is more stable in DMSO compared to H2O (to prevent self-hydrolysis), the substrate is diluted in water (or alternatively AMT buffer) to avoid interference of DMSO with the assay. The reaction is then started by adding the main mixture (reaction solution) to the protein solution or control solution, respectively. Start measuring immediately. The measurement time is 30 minutes, and the measurement interval is 15 seconds. The stock solution of the inhibitor is used as follows: 300 μM orlistat (Sigma-Aldrich, USA) in DMSO, 100 mM PMSF (Roth, Germany) in isopropanol, and 500 mM EDTA (Sigma-Aldrich, USA) in H2O.

[0201] To generate a pH profile of the protein solution, kinetic measurements as described above were performed at the indicated pH values. The added AMT buffer was adjusted to the indicated pH in the pH 4-8 range (0.5 steps) and the kinetics were recorded for each pH value.

[0202] Effect of Tropolone on the Fluorescence of Free Fluorophores

[0203] The effect of tropolone on the fluorescence of HPTS and 4-MU at pH = 5.5 was tested using a target concentration of 10 mM tropolone. A 1:1 dilution series was performed for HPTS and 4-MU with a target concentration range of 3 μM to 96 nM. DMSO served as a control substance for tropolone. In addition, a 1:1 dilution series of tropolone was performed with a target concentration of 10 mM-3.2 μM.

[0204] Embodiment 1: Determination of λex and λem of free fluorophore HPTS

[0205] Aqueous solutions of free fluorophores (HPTS, Sigma-Aldrich) were prepared to record spectra with respect to excitation and emission wavelengths (see Figure 2 A). For the intended use, it is essential that the fluorophore can be used in the pH range of preferably pH=4-8. For the determination of λex and λem, a final 1.5 μM HPTS aqueous solution was prepared using AMT buffer for pH values ​​4 to 8 (0.5 step) by mixing the respective buffer with the HPTS aqueous solution in the plate (composition: 75 μL 4xAMT (variable pH), 75 μL 6 μM HPTS solution, 150 μL fully demineralized H2O). In order to identify possible effects of pH on the intensity of the HPTS fluorescence signal obtained, spectra were recorded at different excitation wavelengths λex=300-500 nm and constant emission wavelength λem=520 nm, and further spectra were recorded at constant excitation wavelength λex=415 nm and different emission wavelengths λem=420-620 nm.

[0206] The highest fluorescence signal, an overall maximum, was observed at λex = 403 nm, and no further changes in intensity were observed for pH values ​​4-6.5. At pH>6.5, a slight loss of intensity was observed with increasing pH. However, compared to the isosbestic point (λex = 413 nm) where no pH dependence was observed, the intensity gain at λex = 403 nm provides higher sensitivity even at pH = 8. For this reason, the excitation wavelength λex = 403 nm was selected for all further investigations. However, it is worth noting that the sensitivity decreases slightly with increasing pH (>6.5).

[0207] The emission maximum is at λem = 512 nm, therefore all measurements are recorded at this emission wavelength unless otherwise mentioned.

[0208] Embodiment 2: Calibration curves allow quantification of free fluorophores

[0209] The calibration curve allows to relate the recorded fluorescence signal to the fluorophore concentration in solution. Therefore, the change in HPTS concentration over a period of time is based on the enzymatic activity and this can therefore be calculated. To generate the calibration curve, serial dilutions of HPTS were prepared and measurements of these dilutions were performed for each pH value of AMT buffer (acetate, MES, TRIS). This buffer was used throughout the experiments because it has a wide buffering range without major changes in ionic strength and osmotic pressure. These separate calibration curves further allow to correct for pH-dependent changes in the fluorescence signal. Figure 2At the top of B, calibration lines are plotted for HPTS concentrations in the range 1.46-3000 nM, and at the bottom, the limits of the linear range are shown using the example of the calibration line at pH=7 for the HPTS concentration range 93.75-6000 nM.

[0210] It can be seen that with increasing pH, the slope of the calibration curve decreases. The concentration at concentration ≥ 3 μM shows a less perfect linear fit (R2 is less than 0.99999) because the linear behavior changes to asymptotic behavior. The RFU value of the HPTS concentration of 6 μM has a deviation of 7.4% from the calibration curve (including 3 μM). Therefore, a calibration curve up to 3 μM was used.

[0211] Embodiment 3: Influence of measurement modes TR and BR on the calibration line

[0212] The Multiwell PlateReader SpektraMax M3 (Molecular Devices, US), in which fluorescence is not read orthogonally to the excitation light, allows two possible measurement modes, top reading (TR) and bottom reading (BR). Therefore, using an aqueous dilution series of HPTS ranging from 1.5 μM to 1.46 nM at pH 4-8 recorded by TR and BR, it was tested whether measurements from above or below gave different results.

[0213] For measurements in TR mode, multiwell plates with a black, opaque bottom were used (96-well, black bottom plates; Greiner Bio-One, Austria), whereas for measurements in BR mode, the plates had a special transparent bottom (96-well, transparent bottom plates, Greiner Bio-One, Austria) that allowed measurements from below. Non-binding plates and medium-binding plates (Greiner Bio-One) were further tested, with the non-binding plates being found to be slightly better. The BR measurement mode yielded a steeper calibration line (data not shown) compared to the TR measurement, which means that smaller concentration changes can be calculated from the BR measurement, corresponding to a higher sensitivity. In the following experiments, measurements were performed in BR measurement mode for OPTS and 4-MUD using non-binding plates.

[0214] Embodiment 4: Hydrolysis of the fluorescent substrate OPTS

[0215] The fluorogenic substrate OPTS (1-octanoyloxy-pyrene-3,6,8-trisulfonic acid, Sigma-Aldrich) consists of pyrene substituted with trisulfonic acid esterified with octanoic acid. Due to its high solubility in H2O (≥2 mM), OPTS represents a substrate for enzymes that convert hydrophilic substrates, such as carboxylesterases.

[0216] A stock solution of the fluorescent substrate in water was prepared. Aqueous solutions with OPTS concentrations ≥ 2.0 mM can be prepared. Solubility can be verified by light scattering experiments.

[0217] The fluorophore HPTS can be released from the substrate (here esterified octanoic acid) by enzymatic or chemical hydrolysis (acidic and alkaline hydrolysis). To evaluate the effect of pH on aqueous solutions of substrates, 225 μL of a 33.3 μM OPTS solution was added to each 75 μL of AMT buffer (with pH=5.5 and pH=8), and the kinetics of fluorophore release were recorded for a total of 2 hours. The results are shown in Figure 3 middle.

[0218] There are clear differences in the slope of the fluorescence signal for different pH values. Based on the recorded calibration curve, the autohydrolysis rate at pH 5.5 was calculated to be 1.58*10 -7 Units (μmol*min-1), and the autohydrolysis rate at pH 8.0 was calculated to be 3.48*10 -6 Unit.Therefore, the hydrolysis rate under pH 8 is about 22 times of pH 5.5, showing that under alkaline pH, the hydrolysis of fluorescent substrate can be observed over a period of time, but only under very low levels under pH 5.5.Autohydrolysis is enhanced along with decreasing chain length, and therefore, it is expected to be disadvantageous from the substrate HPTS ester with saturated unbranched fatty acid less than six carbon atoms.Therefore, suitable substrate will be at least C6 substrate HPTS ester, for example 1-hexanoyloxy-pyrene-3,6,8-trisulfonic acid trisodium salt, 1-heptanoyloxy-pyrene-3,6,8-trisulfonic acid trisodium salt or 1-octanoyloxy-pyrene-3,6,8-trisulfonic acid trisodium salt.In addition, pH should be maintained below pH 8.

[0219] Embodiment 5: Enzymatic hydrolysis of the fluorescent substrate OPTS

[0220] An aqueous solution of commercially available porcine pancreatic lipase PPL was prepared (Sigma-Aldrich, US; 100-500 units / mg protein). According to the manufacturer, this powder contains mainly triacylglycerol lipase, but since it is a homogenized powder from freeze-dried porcine pancreas (crude extract), it is likely to further contain other carboxylesterases and lipases. These enzymes hydrolyze fatty acid esters, and therefore this extract was selected for functional testing.

[0221] To record the reaction kinetics of the substrate OPTS with PPL, a 10 mg / mL PPL aqueous solution was prepared by adding 10 mg PPL to 1 mL H 2 O. The suspension was vortexed for 2 minutes and centrifuged at 14,000 xg for 5 minutes before removing the supernatant.

[0222] With the addition of 30 μL of 250 μM OPTS solution, a reaction mixture of 75 μL AMT buffer (pH=7), 165 μL H2O and 30 μL 10 mg*mL-1 PPL aqueous solution was started. The increase in fluorescence was recorded over 30 minutes with a measurement interval of 15 seconds (n=2). A formulation without PPL (containing only H2O) served as a control (blank). Figure 4 The results of two measurements (blank corrected) are shown. Figure 4 The data shown in indicate that the enzymes present in the PPL extract are able to enzymatically hydrolyze OPTS to HPTS. The calculated reaction rate is 2.89±0.08*10-5 units (μmol*min-1).

[0223] To test the maximum speed v max OPTS solutions of different concentrations were prepared by serial 1:1 dilutions of 10 mM OPTS aqueous solutions. 30 μL of each of these solutions was added to 75 μL AMT buffer (pH=7) and made up to 300 μL with H2O. It was observed that at OPTS concentrations <125 μM, there was no linear relationship (R2≤0.999) between concentration and fluorescence intensity. Therefore, all further measurements were performed at 25 μM OPTS concentrations.

[0224] Embodiment 6: Effects of detergents on the fluorescent substrate OPTS

[0225] Detergents are added to a large number of samples that may be of interest for testing the hydrolytic activity with respect to OPTS. In a complementary assay (for lipophilic substrates) using 4-MUD as substrate, a detergent such as CHAPS is added above the critical micelle formation concentration to solubilize the substrate and open the lid of the lipase that otherwise covers the active site of the lipase. For this purpose, CHAPS was added to a 25 μM OPTS solution with AMT buffer (pH=7) and 1 mg*mL-1 PPL at a final concentration of 10 mM. A second reaction was started in batch without the addition of CHAPS. It was found that CHAPS had a negative effect on the enzymatic hydrolysis of OPTS by PPL ( Figure 5 A). 2.53*10 observed by CHAPS is not included -5 The activity of the unit decreased to 6.16*10 in the presence of 10 mM CHAPS. -7. Interference with the enzymatic hydrolysis can have different causes. Mixed micelles of CHAPS and OPTS may be formed, thus shielding the substrate and making it inaccessible to the active site of the enzyme (Lasic, Martin et al. 1989) or the free fluorophore HPTS may be affected by the presence of CHAPS. Experimental evidence indicates that the accessibility of the substrate OPTS is strongly reduced by CHAPS due to the formation of mixed micelles. Moreover, the determination of esterase activity in a buffer containing detergent is undesirable, since the assay is designed to measure enzymes capable of turnover of hydrophilic substrates, rather than lipases (which may be more active in the presence of detergents due to the open-cap configuration). This is in stark contrast to the previously developed 4-MUD assay for the detection of lipase activity, which is more sensitive in the presence of CHAPS (WO 2022049294A1). It has further been shown that Triton X-100 inhibits this assay, see WO 2022 049294A1. Fig.10 ).

[0226] Further inhibition was tested with the non-ionic detergent polysorbate 20 (Tween 20). Tween 20 is one of the most commonly used detergents in biopharmaceutical products and is often present above its CMC (CMC 10 2 -10 3 μg / ml) was used, with a typical concentration of 0.2-0.4 mg / ml. Target concentrations between 200 μg / mL and 0.098 μg / mL were tested using PPL. Inhibition was not observed until 50 μg / ml at pH 7.0, but higher concentrations reduced the fluorescence signal ( Figure 5 B). Subsequent experiments showed that this is due to the negative effect of polysorbate 20 on the chromophore HPTS. Therefore, the fluorescence signal of HPTS is slightly suppressed at higher concentrations of polysorbate 20, and should therefore not exceed 100 μg / ml, preferably not more than 50 μg / ml. The bulk drug samples analyzed in this study had a polysorbate 20 concentration of 50 μg / ml or less after dilution in the reaction mixture.

[0227] The OPTS assay is intended for in-process control samples of the manufacture of the recombinant protein of interest as a rapid high-throughput assay for purification sequence development and optimization. Most in-process control samples do not contain detergents, such as polysorbate 20. Therefore, this observation does not limit the applicability of the assay. Samples that may contain detergents are mainly final bulk drugs, and may be harvested cell culture fluid (HCCF) due to defoamers. However, due to the high hydrolase activity in HCCF, the sample needs to be diluted, and therefore the potential defoamer reaches a concentration that does not interfere with the assay. For the final product containing polysorbate, unless the polysorbate concentration is higher than the CMC after the sample dilution in the reaction mixture, this should not be negatively affected as in this example. Even the final polysorbate 20 concentration between 50 μg / ml and 100 μg / ml only slightly affects the sensitivity of the assay. In case the polysorbate concentration in the reaction mixture (i.e. after dilution) is clearly above the CMC (e.g. above 100 μg / ml), the UF / DF samples (i.e. before polysorbate addition) can be used to determine the hydrolytic activity using the OPTS assay. However, we note in this context that this assay is particularly useful for high-throughput analysis of IPC samples in small volumes for process optimization, which typically do not contain polysorbate.

[0228] Finally, the activity of the OPTS assay in buffer as described in WO 2022 / 047416 A1 (page 37) was tested. For this purpose, 150 mM Tris, 0.25% (w / v) Triton X-100, 0.125% (w / v) gum arabic (TTG buffer), pH = 8, containing 1 mg*mL-1 PPL and a final OPTS concentration of 100 μM, was tested and compared with 100 μM OPTS, 1 mg / ml PPL in AMT buffer (without detergent) at pH 8. The OPTS concentration was increased from 25 μM to 100 μM to match the substrate concentration of 100 μM 4-MU containing the fluorescent substrate used in WO 2022 / 047416 A1. Triton X-100 (MW = 625 g / mol) has a critical micelle concentration (CMC) of 0.22 to 0.24 mM, and thus 0.25% (w / v) Triton X-100 (4 mM) is well above its CMC. It was found that TTG buffer had a negative effect on the enzymatic hydrolysis of OPTS by PPL ( Figure 6In a detergent-free buffer (AMT buffer), an enzyme-mediated hydrolysis of OPTS was observed to be 3-4 times higher than in TTG buffer containing Triton X-100. Despite the use of Triton X-100 concentrations above the CMC, the incomplete inhibition may be explained by an excess of OPTS, potentially resulting in some substrate being accessible outside the formed micelles (self-hydrolysis was subtracted from the measured signal). For Triton X-100, an aggregation number of about 80 ( N. et al., Micelles Determined by Light and Small-Angle X-Ray Scattering Techniques. In Mittal, KL (ed.) Surfactants in Solution, Springer Boston, MA, pp. 181-195), about 50 μM micelles are formed, and therefore a substrate concentration of 100 μM will be present in molar excess. Nevertheless, the buffer and conditions described in WO 2022 / 047416A1 are not suitable for the OPTS assay of the present invention. In particular, it is undesirable to determine esterase activity in a buffer containing a detergent (and particularly a detergent above its CMC). The assay is designed to measure enzymes that can turn over hydrophilic substrates rather than lipases, so omitting the detergent is conducive to detecting carboxylesterases, and potentially further reducing the background detection of lipase activity, which may be more active in the presence of a detergent (due to the accessibility of the substrate in the open-cap configuration and micelles). Therefore, buffers used to measure the hydrolysis of hydrophilic substrates should be free of detergents, or at least not exceed the CMC of detergents.Thus, the conditions described herein for the OPTS assay, especially the omission of detergents, render the assay specific for carboxylesterases acting on hydrophilic substrates.

[0229] The results show that the buffer described in WO 2022 / 047416 A1 cannot be used for the OPTS buffer herein due to the presence of detergents. In addition, at pH 8.0, autohydrolysis increased, resulting in reduced sensitivity of the assay, and it was found that autohydrolysis was more critical for OPTS than 4-MUD, especially at pH 8.0 (see Figure 3 ). Additionally, most samples to be analyzed using the OPTS assay are in the acidic rather than basic range.

[0230] Embodiment 7: Use the OPTS assay to determine the hydrolytic activity of antibodies in solution

[0231] The purpose of OPTS determination is to characterize the esterase (e.g., carboxylesterase) activity in samples containing recombinantly produced proteins such as antibodies. The sample tested is a bulk drug sample from 9 different antibody preparations, including IgG1 and IgG4 monoclonal antibodies and bispecific IgG-like forms, which are produced in CHO K1 or DG44 cells. The bulk drug sample comprises a small amount of contaminating host cell proteins that stabilize (buffer material, additives and detergents for adjusting ionic strength) and potentially demonstrate hydrolytic enzyme activity. In order to verify whether enzymatic activity is involved, the antibody sample is heat pretreated at 50 ° C in ThermoMixer C (Eppendorf, Germany), then cooled to RT (passively) before kinetic measurements as described. The activity in all samples is reduced with increasing thermal incubation, which indicates enzymatic activity.

[0232] 9 different antibody (Ab1-Ab9) samples were tested using the OPTS assay. As a control, measurements were performed using the same buffer solutions as used in the antibody samples, respectively.

[0233] For some antibody solutions, the control showed slightly higher activity than the samples (data not shown), and these samples all contained histidine at about 25 mM. Since histidine has previously been reported to mediate hydrolytic activity in aqueous solutions similar to esterases (Delort, Nguyen-Trung et al. 2006, Mason, McCracken et al. 2010, Amano, Kobayashi et al. 2014, Xu, Chen et al. 2017), the samples were dialyzed against 0.002% NaCl using a two-step dialysis with a molecular weight cutoff (MWCO) of 20K. For preparative dialysis, a pre-wetted dialysis cassette was filled with 2 ml of antibody solution and placed in a beaker containing 1 L of NaCl (0.002% w / v) solution with gentle stirring. After one hour, the 1 L NaCl solution was replaced with a fresh NaCl (0.002% w / v) solution and dialyzed for another two hours with gentle stirring. For histidine concentrations below 200 μM, activity was found to be 10 -7 The results are in the low range of 1000 Å (data not shown), and thus the effect of this buffer component is almost negligible. In the following, the dialyzed bulk drug sample was used for determination. The same solution (final solution outside the dialysis cassette) was used as a control sample to be subtracted from the test sample.

[0234] Figure 7 The hydrolysis activity for different antibody solutions after dialysis using the OPTS assay is shown. A wide range of hydrolysis activities was observed, varying by more than an order of magnitude (from 1.24*10 -7 Unit to 3.28*10 about Ab5-6 units), which can be explained by the presence of different types or amounts of esterases in the protein solution. Figure 7 The results shown in were all determined at a pH of 5.5, corresponding to the pH of the solution under investigation. Carboxylesterases generally show their maximum hydrolytic activity at about pH 6. Therefore, it appears that no carboxylesterase activity was detected in protein solutions 1, 4, 8 and 9.

[0235] The substrate OPTS (C8 chain length) has a chain length that is well in the transition region between short-chain and long-chain fatty acid esters. Therefore, it is expected that while primarily carboxylesterase activity is measured, some lipase activity may also be detected.

[0236] To further characterize the detected activity, inhibition of hydrolysis activity was tested in all 9 antibody samples using the lipase inhibitor orlistat (10 μM), the protease inhibitor PMSF (1 mM), and the metal chelator EDTA (10 mM). The inhibitors were added to the samples after dialysis before the addition of the master mix freshly mixed with the substrate, and measured at 15 second intervals for 30 minutes. Orlistat, PMSF, or EDTA did not significantly reduce the hydrolysis activity measured in any sample (data not shown).

[0237] Embodiment 8: Using the 4-MUD assay to determine hydrolytic activity in protein solutions

[0238] The data generated using the OPTS assay were compared to an established micelle-containing assay using 4-MUD as substrate ( Figure 8 ) was compared with the assay developed to detect the hydrolytic activity of lipases.

[0239] This 4-MUD assay was used to examine the same protein solution samples that were examined using the OPTS assay. Care was taken to keep the experimental conditions identical to allow a reliable comparison of the results, i.e., same volume of antibody sample, measurements were performed at pH 5.5 and 25°C, and the kinetics were recorded in BR measurement mode at 15 s intervals for a total of 30 min. The reaction mixtures differed only in the substrate and substrate concentration (30 μM 4-MUD) and the use of CHAPS (Roth, Germany) as detergent, and different substrate-specific excitation wavelengths λex and emission wavelengths λem.

[0240] The kinetic results determined using the 4-MUD assay are shown in Figure 8 Again, a wide range of hydrolytic activities was observed, varying by more than an order of magnitude (1.8*10 -7 Units and 2.3*10 in protein solution 8 -6Units). Protein solutions 6, 7, 8 and 9 had a target concentration of 100 μg*mL-1 of polysorbate 20 (Serva, Germany). A qualitative comparison of the hydrolytic activity detected using OPTS or 4-MUD as substrate is shown in Fig. 9 middle.

[0241] according to Fig. 9 The data shown in do not allow for a clear trend to be drawn, comparing the hydrolytic activities detected using the OPTS assay and the 4-MUD assay. Samples that showed relatively high activity in the OPTS assay (e.g., Ab5) showed very low activity in the 4-MUD assay. In contrast, protein solution 4 showed high activity in the 4-MUD assay, but only very low hydrolytic activity in the OPTS assay. Thus, given that the OPTS assay predominantly detects carboxylesterase activity, while the 4-MUD assay predominantly detects lipase activity, carboxylesterase appears to be primarily present in samples 2, 5, 6, and 7, while lipase appears to be primarily present in samples 1, 4, and 9.

[0242] In sample Ab3, the hydrolytic activities detected using the OPTS assay and the 4-MUD assay were in the same range, while in protein solution 8, almost no hydrolytic activity was detected in any assay. Protein solution 5 showed the most obvious difference between the two substrates, showing almost no hydrolytic activity using the 4-MUD assay, while the highest hydrolytic activity of all the tested samples was detected using the OPTS assay. This indicates that the hydrolytic activity of enzymes such as carboxylesterases using hydrophilic substrates seems to very strongly dominate the hydrolytic activity of lipases.

[0243] Embodiment 9: Effects of inhibitors on hydrolysis activity in the 4-MUD assay

[0244] As previously tested in samples analyzed using the OPTS assay, the effects of the inhibitors orlistat (10 μM), PMSF (1 mM), and EDTA (10 mM) were also tested in all nine antibody samples using the 4-MUD assay. Fig.10 The results in show the hydrolysis activity in the presence of the inhibitor relative to the same sample without added inhibitor (100%).

[0245] Fig.10It was shown that the obvious inhibition of the hydrolysis activity by the lipase inhibitor orlistat (10 μM) occurred in all 9 antibody samples examined. The residual activity obtained was within the range of 18-21% of the hydrolysis activity without the addition of the inhibitor. For PMSF, a slight inhibition of the hydrolysis activity was observed in all protein solutions except the antibody solution Ab1. The residual activity ranged from 72% in protein solution 6 to 28% in antibody solution Ab2. This indicates that the hydrolysis activity observed in this sample is mainly due to the enzyme with nucleophilic serine in the active site. On the other hand, the addition of EDTA showed no inhibition in almost any sample. It is therefore concluded that the hydrolysis activity detected in antibody solutions Ab1-Ab9 is not metal-dependent. The results of different activities using the corresponding antibody solutions in OPTS and 4-MUD assays are summarized in Table B below, where (++) means a strong effect, (+) means a weak effect, and (-) means no significant effect.

[0246] Table B

[0247]

[0248] As can be seen from Table B, when OPTS was used as a substrate, none of the inhibitors showed a significant effect on the detected hydrolytic activity. In contrast, when 4-MUD was used as a substrate, the specific lipase inhibitor orlistat showed a strong inhibition of the detected hydrolytic activity. In addition, the serine protease inhibitor PMSF showed a significant inhibition of the hydrolytic activity detected in antibody samples Ab2 and Ab5 using 4-MUD as a substrate. The fact that the addition of EDTA did not show inhibition of the hydrolytic activity in the OPTS assay or the 4-MUD assay suggests that the hydrolase present in the tested protein solution is not a metalloenzyme.

[0249] The inhibitory effect of orlistat is due to the acylation of the serine in the catalytic triad of the enzyme active site (Al-Suwailem, Al-Tamimi et al. 2006), while PMSF is also an inhibitor that binds to the serine in the active site (James 1978). Therefore, these two inhibitors have in common that they render the active site more inaccessible to the substrate to be converted and therefore belong to the class of competitive inhibitors.

[0250] Further, the recently described allosteric inhibitor of the lipase α-tropolone has been tested. Due to its good solubility in water, this inhibitor may be suitable for further characterization of the enzyme activity detected by the OPTS assay. However, tropolone at 10 μM demonstrated a strong effect on both the free fluorophores HPTS (detected in the OPTS assay) and 4-methylumbelliferone (4-MU) (detected in the 4-MUD assay), suggesting that the effect of tropolone on the previously described hydrolytic activity is most likely due to its effect on the fluorescence activity of the free fluorophores (fluorophore quenching), rather than an inhibitory effect.

[0251] Embodiment 10: The hydrolytic activity of lipases detected using the OPTS assay

[0252] Further, purified commercially available lipases with unknown substrate specificity were analyzed using the 4-MUD and OPTS assays. First, the hydrolysis of both soluble (OPTS) and hydrophobic (4-MUD) carboxyl esters was investigated, as well as the effects of orlistat, PMSF and EDTA on the hydrolytic activity of the lipase. The results are shown in Fig.11 middle.

[0253] Lipases generally showed significantly higher activity in the micelle-based 4-MUD assay compared to the OPTS assay. Only low to no activity was found with the OPTS assay. This indicates that polar hydrophilic esters are not substrates for this hydrolase.

[0254] Further, no significant effect of the inhibitors on the hydrolytic activity was shown in the OPTS assay. For the hydrolytic activity detected using the 4-MUD substrate, orlistat almost completely inhibited the detected hydrolytic effectiveness, while PMSF and EDTA had only a slight effect. Since the lipase tested is not a serine protease, inhibition is not expected using the serine protease inhibitor PMSF.

[0255] In addition, the lipase was tested for its pH dependence in the OPTS and 4-MUD substrate assays. For this purpose, the hydrolytic activity was examined at pH = 4-8. The results are shown in Fig.12 middle.

[0256] Fig.12 It was shown that very low hydrolytic activity was detected using OPTS as a substrate, and slightly increased at pH 6.0 or higher. Using 4-MUD as a substrate, the detected hydrolytic activity was higher at low pH, with a maximum at pH 5.5. In addition, at more alkaline pH, the detected activity was strongly reduced. Lipase is a lysosomal lipase, and therefore the finding of an optimum pH at pH 5.5 is consistent with the lysosomal pH at about pH 4.5 to 5.5.

[0257] The different results obtained using OPTS and 4-MUD as substrates are further confirmation of previous findings that the assay detects the hydrolytic activities of different enzymes, such as carboxylesterase using OPTS and lipase using 4-MUD as substrate.

[0258] Comparing the hydrolysis activities detected using OPTS and 4-MUD as substrates, along with the antibody solution Ab9, increasing activity with increasing pH was observed using OPTS as a substrate, and decreasing activity was observed using 4-MUD as a substrate ( Fig.13 ), where overall stronger activity was observed with the 4-MUD substrate. For the antibody solution Ab9, maximum activity was present in the acidic range, pH = 4.5-5.

[0259] In contrast, antibody solution Ab2 showed the opposite behavior, with low activity using 4-MUD substrate and high activity using OPTS ( Fig.14 A and B). In both cases the activity increases with increasing pH.

[0260] exist Fig.15 In the OPTS assay, a similar behavior was shown for antibody solution Ab5, but with the 4-MUD substrate, the activity was significantly lower. In addition, the pH profile with 4-MUD was slightly different, showing a local maximum in the acidic range (pH = 4-4.5), lower activity between pH 5 and 6.5 and an increase at higher pH. However, the pH profile measured with OPTS showed a similar behavior to protein solution 2. The finding of almost no activity in the 4-MUD assay suggests that the lipase is active in antibody solution Ab5 (as well as antibody solutions Ab6 and Ab8; see Fig. 9 ) is absent or present only in very low concentrations.

[0261] The commercial lipase tested ( Fig.12 ) and antibody solution Ab2( Fig.14 ) or antibody solution Ab5( Fig.15 ) did not show similarity. However, antibody solution Ab9 showed similar profiles for the data of the OPTS assay and the 4-MUD substrate assay at pH 4-8. This may be an indication of the presence of this lipase in antibody solution Ab9. Since the hydrolysis activities in the OPTS assay and the coumarin substrate assay are of the same order of magnitude, it seems that there are other enzymes that also contribute to the hydrolysis activity.

Claims

1. A method for detecting carboxylesterase activity of contaminating host cell proteins in a sample containing a recombinant protein of interest produced in a eukaryotic cell, wherein include: (a) providing at least one sample comprising a recombinant protein of interest produced in eukaryotic cells in cell culture and at least one contaminating host cell protein; (b) contacting the at least one sample with a reaction solution (comprising a hydrophilic substrate) to form a reaction mixture, wherein the reaction solution comprises: (i) a buffer having a pH of about pH 4 to about pH 8, (ii) a hydrophilic substrate, wherein the substrate is a saturated unbranched fatty acid (C6-C12) ester of 1-hydroxypyrene-3,6,8-trisulfonic acid or a salt thereof (substrate HPTS ester), and (iii) optionally a non-buffering salt; (c) incubating the sample and the substrate in the reaction mixture; (d) detecting carboxylesterase activity of at least one contaminating host cell protein by measuring the hydrolysis of a substrate HPTS ester and detecting the fluorescence intensity of the released chromophore 1-hydroxypyrene-3,6,8-trisulfonic acid or a salt thereof (HPTS); Optionally, while incubating the sample and substrate in the reaction mixture according to step (c), the hydrolysis is measured by detecting the fluorescence intensity of the released chromophore HPTS over a period of time.

2. The method of claim 1, wherein (a) incubating the sample and substrate in the reaction mixture for any period of time between 2 minutes and 5 hours, 2 minutes and 3 hours, 2 minutes and 2 hours, or 2 minutes and 0.5 hours; and / or (b) analyzing multiple reaction mixtures in parallel; and / or (c) wherein the reaction mixture has a volume of 300 μl or less.

3. The method of claim 1 or 2, wherein the fluorescence of the released chromophore HPTS is determined using an excitation wavelength in the range of 401-405 nm and an emission wavelength in the range of 510-516 nm.

4. The method of any one of the preceding claims, wherein the substrate HPTS ester is selected from 1-octanoyloxy-pyrene-3,6,8-trisulfonic acid or a salt thereof (OPTS), 1-nonanoyloxy-pyrene-3,6,8-trisulfonic acid or a salt thereof and 1-decanoyloxy-pyrene-3,6,8-trisulfonic acid or a salt thereof.

5. The method according to any one of the preceding claims, wherein the method further comprises include: (bi) contacting the at least one sample of step (a) comprising the recombinant protein of interest produced in eukaryotic cells in cell culture and at least one contaminating host cell protein with a reaction solution comprising a lipophilic substrate in a separate reaction setup to form a reaction mixture, wherein the reaction solution comprises: (i) a buffer having a pH of about pH 4 to about pH 8, (ii) a lipophilic substrate comprising the chromophore 4-methylumbelliferone (4-MU) in the form of a 4-MU ester, wherein the 4-MU ester is a saturated unbranched fatty acid (C6-C16) 4-MU ester, (iii) optionally a non-buffering salt, and (iv) a non-denaturing detergent having no ester bonds, wherein the detergent is a non-ionic or zwitterionic detergent, (ci) incubating the sample and substrate in the reaction mixture of step (bi); and (di) detecting lipase activity of at least one contaminating host cell protein by measuring hydrolysis of a substrate 4-MU ester and detecting the fluorescence intensity of the released chromophore 4-MU; Optionally, while incubating the sample and substrate in the reaction mixture according to step (ci), the hydrolysis is measured by detecting the fluorescence intensity of the released chromophore 4-MU over a period of time.

6. The method of claim 5, wherein (a) the lipophilic substrate is selected from 4-methylumbelliferyl octanoate, 4-methylumbelliferyl nonanoate, 4-methylumbelliferyl decanoate (4-MUD), 4-methylumbelliferyl undecanoate and 4-methylumbelliferyl dodecanoate; (b) the detergent has a final concentration in the reaction mixture that is higher than its critical micelle concentration in the reaction mixture; and / or (c) the detergent (i) selected from CHAPS, CHAPSO and Zwittergent, preferably CHAPS; or (ii) is CHAPS and is provided in the reaction mixture at a final concentration of about 8 mM to about 20 mM, preferably about 8 mM to about 15 mM, more preferably about 10 mM; or (iii) It is neither polyethylene glycol tert-octylphenyl ether (Triton X-100) nor polyethylene glycol nonylphenyl ether (NP-40).

7. The method of any of the preceding claims, wherein the buffer comprises one or more buffer substances selected from the group consisting of formic acid, acetic acid, lactic acid, citric acid, malic acid, maleic acid, glycine, glycylglycine, succinic acid, TES (2-{[tris(hydroxymethyl)methyl]amino}ethanesulfonic acid), MOPS (3-(N-morpholino)propanesulfonic acid), PIPES (piperazine-N,N'-bis(2-ethanesulfonic acid)), MES (2-(N-morpholino)ethanesulfonic acid), Tris base, Tris, Bis-Tris, Bis-Tris-propane, Bicine (N,N-bis(2-hydroxyethyl)glycine), HEPES (4-2-hydroxyethyl-1-piperazineethanesulfonic acid), TAPS (3-([tris(hydroxymethyl)methyl]amino}propanesulfonic acid), Tricine (N-tris(hydroxymethyl)methylglycine), Na 2 HPO 4 and NaH 2 PO 4 .

8. The method of any one of the preceding claims, wherein the buffer (a) has a pH of about 5 to about 7.5, preferably the buffer has a pH of about 5.5 to about 7.0; and / or (b) is a multi-component buffer having a buffer range of at least about pH 5 to at least about pH 7.5, preferably at least about pH 4 to at least about pH 8.

9. The method of any one of the preceding claims, wherein (a) The non-buffer salt is selected from NaCl, KCl and CaCl 2 , preferably wherein the non-buffering salt is NaCl or KCl; and / or (b) the non-buffering salt has a concentration in the reaction mixture of about 100 mM to about 200 mM, preferably about 130 mM to about 170 mM, more preferably about 140 mM to about 150 mM; and / or (c) the ionic strength of the non-buffering salt is about 200 mM or less in the reaction mixture, preferably about 150 mM or less in the reaction mixture; and / or (d) the cumulative ionic strength of the buffer and non-buffer salt in the reaction mixture is about 450 mM or less, preferably about 400 mM or less, and more preferably about 350 mM or less in the reaction mixture.

10. The method of any one of the preceding claims, wherein (a) the at least one sample is a harvested cell culture fluid (HCCF), an in-process control (IPC) sample, a UF / DF filtrate, a drug substance sample, or a drug product sample; (b) the recombinant protein of interest is produced in CHO cells, and the at least one contaminating host cell protein is a CHO host cell protein (CHOP); (c) the recombinant protein of interest is not a carboxylesterase or a lipase and / or an enzyme having carboxylesterase or lipase activity; and / or (d) The recombinant protein of interest is selected from the group consisting of antibodies, antibody fragments, antibody-derived molecules and fusion proteins.

11. A method for producing a recombinant protein of interest, comprising the following steps (i) cultivating eukaryotic cells expressing the recombinant protein of interest in cell culture; (ii) harvesting the recombinant protein of interest; (iii) purifying the recombinant protein of interest; and (iv) optionally formulating the recombinant protein of interest into a pharmaceutically acceptable formulation suitable for administration; and (v) obtaining at least one sample comprising the recombinant protein of interest in steps (ii), (iii) and / or (iv); Wherein the method further comprises detecting carboxylesterase activity in a sample comprising the recombinant protein of interest and at least one contaminating host cell protein, comprising: (a) providing at least one sample obtained in step (v), the sample comprising a recombinant protein of interest produced in eukaryotic cells in cell culture and at least one contaminating host cell protein; (b) contacting the at least one sample with a reaction solution comprising a hydrophilic substrate to form a reaction mixture, wherein the reaction solution comprises: (i) a buffer having a pH of about pH 4 to about pH 8, (ii) a hydrophilic substrate, wherein the substrate is a saturated unbranched fatty acid (C6-C12) ester of 1-hydroxypyrene-3,6,8-trisulfonic acid or a salt thereof (substrate HPTS ester), and (iv) optionally a non-buffering salt; (c) incubating the sample and the substrate in the reaction mixture; and (d) detecting carboxylesterase activity of at least one contaminating host cell protein by measuring the hydrolysis of a substrate HPTS ester and detecting the fluorescence intensity of the released chromophore HPTS; The method optionally further comprises detecting lipase activity in the sample, comprising: (bi) contacting the at least one sample of step (a) comprising the recombinant protein of interest produced in a eukaryotic cell and at least one contaminating host cell protein with a reaction solution comprising a lipophilic substrate in a separate reaction setup to form a reaction mixture, wherein the reaction solution comprises; (i) a buffer having a pH of about pH 4 to about pH 8, (ii) a lipophilic substrate comprising the chromophore 4-methylumbelliferone (4-MU) in the form of a 4-MU ester, wherein the 4-MU ester is a saturated unbranched fatty acid (C6-C16) 4-MU ester, (iii) optionally a non-buffering salt, and (iv) a non-denaturing detergent having no ester bonds, wherein the detergent is a non-ionic or zwitterionic detergent, (ci) incubating the sample and the substrate in the reaction mixture; (di) detecting lipase activity of at least one contaminating host cell protein by measuring the hydrolysis of a 4-MU ester and detecting the fluorescence intensity of the released chromophore 4-MU; Optionally, while incubating the sample and substrate in the reaction mixture according to step (c) or (ci), respectively, the hydrolysis is measured by detecting the fluorescence intensity of the released chromophore HPTS and / or 4-MU over a period of time.

12. The method of claim 11, comprising obtaining at least one sample comprising the recombinant protein of interest in the following - step (ii), wherein the sample is harvested cell culture fluid (HCCF) or cell lysate; - step (iii), wherein the sample is an in-process control (IPC) sample; and / or - step (iv), wherein the sample is a UF / DF sample, a drug substance sample or a drug product sample; Preferably, the method comprises obtaining in step (iii) at least one sample comprising the recombinant protein of interest produced in eukaryotic cells in cell culture and at least one contaminating host cell protein, which comprises obtaining the at least one sample before and after affinity chromatography, before and after acid treatment, before and after depth filtration, and / or before and after ion exchange chromatography, preferably anion exchange chromatography or cation exchange chromatography.

13. A kit for determining contaminating carboxylesterase activity and / or lipase activity in a sample comprising a recombinant protein of interest, the kit comprising: (i) a buffer having a pH of about pH 4 to about pH 8; (ii) a hydrophilic substrate and a lipophilic substrate, wherein (a) the hydrophilic substrate is a saturated unbranched fatty acid (C6-C12) ester of 1-hydroxypyrene-3,6,8-trisulfonic acid or a salt thereof (substrate HPTS ester); and (b) the lipophilic substrate comprises the chromophore 4-methylumbelliferone (4-MU) in the form of a 4-MU ester, wherein the 4-MU ester is a saturated unbranched fatty acid (C6-C16) 4-MU ester (substrate 4-MU ester); and optionally (iii) non-buffered salts; and / or (iv) a non-denaturing detergent having no ester bond, wherein the detergent is a non-ionic or zwitterionic detergent.

14. The kit of claim 13, wherein (a) the hydrophilic substrate HPTS ester is selected from 1-octanoyloxy-pyrene-3,6,8-trisulfonic acid or its salt (OPTS), 1-nonanoyloxy-pyrene-3,6,8-trisulfonic acid or its salt and 1-decanoyloxy-pyrene-3,6,8-trisulfonic acid or its salt; and / or (b) The lipophilic substrate 4-MU ester is selected from 4-methylumbelliferyl octanoate, 4-methylumbelliferyl nonanoate, 4-methylumbelliferyl decanoate (4-MUD), 4-methylumbelliferyl undecanoate and 4-methylumbelliferyl dodecanoate.

15. The kit of claim 13 or 14, wherein the kit further comprises one or more microtiter plates having 96 wells or multiples of 96 wells.

16. Use of a hydrophilic substrate HPTS ester and a lipophilic substrate 4-MU ester as substrates for detecting carboxylesterase and lipase activity of at least one contaminating host cell protein in a sample in an assay, said sample comprising a recombinant protein of interest produced in eukaryotic cells in cell culture, preferably wherein said recombinant protein is produced in CHO cells and the at least one contaminating host cell protein is a CHO host cell protein (CHOP), wherein the hydrophilic substrate is a saturated unbranched fatty acid (C6-C12) ester of 1-hydroxypyrene-3,6,8-trisulfonic acid or a salt thereof (substrate HPTS ester), and The lipophilic substrate is a saturated unbranched fatty acid (C6-C16) 4-MU ester.

17. Use of a hydrophilic substrate HPTS ester as a substrate for detecting carboxylesterase activity of at least one contaminating host cell protein in a sample in an assay, wherein the sample comprises a recombinant protein of interest produced in eukaryotic cells in cell culture, preferably wherein the recombinant protein is produced in CHO cells and the at least one contaminating host cell protein is CHO host cell protein (CHOP). The hydrophilic substrate is a saturated unbranched fatty acid (C6-C12) ester of 1-hydroxypyrene-3,6,8-trisulfonic acid or a salt thereof (substrate HPTS ester).